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1. INTRODUCTION 
 
  Siddha system is one of the oldest systems of medicine in India.  Siddha 
system is based on truth and philosophy.  This medicine system has the unique feature 
like removal the root cause of the disease and perfect remedy for body, mind and soul.  
The Siddha system has explained that five basic elements namely, 1. Prithivi 2. Appu  
3. Theyu  4.Vayoo 5. Agayam 
 
According to the Siddhars concept 
 
அzட{தி உளேத பzட 
பzட{தி  உளேத அzட 
-சyைட «ன ஞான. 
 
                                 The Siddha system based on namely vatham, pitham and kabam. 
Siddha is the first system to emphasize on food habits. If human beings have any 
alteration in food habits, it will affect the vital elements of their body. According to 
Thiruvalluvar in his Thirukkural, 
 
                             மா²பாலாத உz ம²{¢zண 
                             ஊ² பாைல உயƫt. 
 
                  Yugi one of the ancient Siddhar had classified the diseases into 
4448 types.  He had classified urinary disorders into 
 
1. Neerinai Arukkal Noigal 
 
2. Neerinai Perukkal Noigal 
 
               Kalladaippu disease comes under Neerinai Arukkal Noigal. 
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In our Siddha system Urolithiasis may be compared to Kalladaippu. 
Kalladaippu is the most common diseases of present society due to modern life style 
and abnormal diet habits clinical features of Kalladaippu are lower abdominal pain, 
dysuria, oliguria, burning micturition, nausea, vomiting haematuria and fullness of 
abdomen.  
 
The efficacy of invasive therapies such as extra corporal shock-wave 
lithotripsy and ureteroscopy has been proven by several studies.  However these 
techniques are not risk free and they are problematic and quite expensive and 
complication. 
  
In our Siddha system the number of drugs has been prepared from the 
medicinal plants which are source of drugs for Kalladaippu. 
  
According to Agasthiyar, in his vathiya kaviyam 1500 there was a preparation 
of MAVILINGU KASAYAM which is indicated for Kalladaippu and to evaluate its 
Lithotriptic, Diuretic, Anti-Spasmodic (smooth muscle relaxants) activities. 
 
We must praise safe guard and follow the Siddha systems of medicine and 
also furnish it to take up with the up to date advancement. 
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2. AIM AND OBJECTIVES 
 
AIM: 
 
The main aim of this dissertation work is to do a scientific validation of 
MAVILINGU KASAYAM and its efficacy in treating Kalladaippu disease. 
 
Urolithiasis constitutes one of the commonest diseases in our country and pain 
due to urolithiasis is known as worse than that of labor pain.  In India, 5% of people 
are seeing affected by kidney stones and 8-10% people who have life time risk of 
passing the kidney stone.  The recurrence rate for urinary calculi is very high, 
approximately 50% among the Indian population. 
 
OBJECTIVES: 
 
 The main objective of the present study is to safety and efficacy of the 
mavilingu kasayam in the treatment of kalladaippu, the following methodology was 
adopted to evaluate the drug and its standardization studies. 
 
 Collection of literature evidence regarding the trial medicine. 
 
 Identification of the drugs in the mavilingu kasayam. 
 
 Preparation of the trial medicine as per the text. 
 
 Physic-chemical analysis of the test drug 
 
 Evaluation of the toxicity of the test drug. 
 
 Evaluation of pharmacological activity of the test drug. 
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3. REVIEW OF LITERATURE 
 
3.1 AERVA LANATA 
3.1.1GUNAPADAM ASPECT 
 
சி²பைள – chirukanpeelai                                       
Aerva lanata 
 
OTHER NAME: 
 
 Chirukan peelai, karpaethi, pasanapaethi kanpeelai. 
 
CHIRUPEELAI OTHER NAME: 
  
 சி²பைள ேபƫதைனேய ெச~பtேக¶ 
  ெசயமான பாஷாண ேபதியாx 
 சி²பைள சuகி சிலா ேபதா 
  ேபதனாைசேவா பலேபத{ ¢}மியா 
 ந²ªைள நாக{தின ச{¢¯ேவ யா 
  நலமா­~©v ச{ைத நாசமாtகிt 
 ச²ªைள{ திƬேதாஷ ­Ƭ­மாx 
  ெச~பயேதாƫ ேபெரலா சி²பைளtேக. 
                                                 
  Bogar nigandu-1700 
 
 Pasana paethi, Sangisilapaethasum, Palapaetha thunmi, Nagaththin sathuru, 
Uppuchaththai nasamakki Thiridhosauri. 
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VERNACULAR NAME: 
 
English  - Comman way side weed  
Telugu   - Pindi-kanda 
Sanskrit   - Pashanabhed 
Malayalam   - Cherupila 
 
PARTS USED: 
 
 Whole plant 
 
ORGANOLEPTIC CHARACTERS: 
 
Taste     - bitter 
Potency   - heat 
Biotransformation              - pungent 
 
PROPERTIES: 
 
Cuvai     - kaippu 
Gunam    - ilaku kurmai 
Virium    - veppam 
Pirivu     - karppu 
  
                    - The Siddha pharmacopeia of India part 1  
ACTION: 
 
              Diuretic  
              Lithotriptic 
               - Gunapadam mooligai vagupu      
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Lithotriptic 
Diuretic 
Astringents 
Bitter 
Emollient 
Vermifuge 
Suppurative 
                                       - Indian medicinal plants vol – 2 
 
Anthelmintic  
Demulcent  
         -medicinal plants in India vol-1  
Demulcent  
Diuretic  
- Materia medica of India and their therapeutics  
Anthelminitic  
Diuretic  
     -Glossary of Indian medicinal plants 
 
Diuretic  
Demulcent  
-  
- Wealth of India vol II-A and Glossary of Indian medicinal plants. 
 
 
 
GENERAL CHARACTERISTICS : 
 
பாz ெப¯பா பகƫ ¬{திரtகிƬvச 
ªzட திƬேதாடமிைவ ேபாuகாz-தாz~ 
பƬய ேவைள{ ¢ர{¢ பாரவயt கzணாய 
சிறிய பைளtv சிைத{¢ 
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நரைட~© கலைட~© நuகா ட ைல 
ேபƬட இர{த கண ேபாt காz- வாƬ 
ªz«ைலேய ேகளா ெபா¯|¢ சி²பைள 
யாமி¢ கேபதி அறி. 
 
 Kalladaippu (kidney stone), pandu (anemia), (menorrhogia), neererichal 
(burning micturition), muppini, neeradaippu, kudar soolai, kuruthi soodu. 
 
சி²பைள ண{ைத ேகyபா 
உ²சீத லேவ நிtத உயƫ பரேமகx ைல 
ெசறி ¬{ரt¯vர ¬ல திƬேதாஷ பலிகாேராக 
ெப¯ }ம மிதயேராக ேபƫதி வதி ெச­. 
 
Piramagam  
Soolai  
Moothirakirucharam  
Moolam  
Thiridhosam  
Kunmam  
Iruthayarogam  
  
இ¯ வத~ பைள தமா வலu நƫt கலைட~©  
ெப¯கிய பாz வ tக ெபƬய ைபசாசேதாஷ 
ம¯வய வாதர{த மz¯ மைலய} பzணாtேகா 
ெடா¯வடா தி{¢ காறி§² நய வட{ைத தƫt 
 
 
Neeradippu 
Kalladaippu  
Pandu  
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Veekam  
Paisasa dhosam  
Vadha raktham  
Sarpa vizham  
-pathartha guna mangari 
 
 
MEDICINAL USES: 
 
 The flowers are used to cure the kidney stone and gonorrhea. 
 
 The roots and flowers are used for cure the headache. 
 
 The whole plant was used in lithiasis, cough, indigestion, sorethoroat, wounds, 
and diabetes. 
 
 The plant was used to treat lithiasis boils, cephalgia, and cough. 
 
- Indian medicinal plants vol-1  
 
 Plant is used as antidote against poisoning of arsenic. 
 
-Materia medica of Indian and their therapeutics  
 
 Roots are credited with tonic properties and given to pregnant women. 
 
-The wealth of India volume II A 
  
 The plant decoction is used in catarrh of bladder. 
 
 The root paste is applied on the forehead in headache. 
-Hand book of medicinal plant 
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 The decoction of the plant can dissolve kidney stones in a few days, which is 
scientifically proven.  It is also a good remedy for bladder stones.  Aerva 
Lanata flowers are also used for this purpose. 
 
 It is used as a treatment for gonorrhea. 
 
 The roots of Aerva Lanata are used for the treatment of snake bite. 
 
 The decoction of root and flowers gives relief from headache. 
 
 The decoction of the root is also used as a tonic during pregnancy. 
 
 Roots of Aerva Lanata are effective as demulcents. 
 
 Juice obtained from the leaves of Aerva Lanata is used as a remedy for painful 
urination and kidney stones.  Advised to be taken in small quantities. 
 
 The decoction of the leaves of Aerva Lanata is used to treat sore throat by 
gargling and also used against guinea-worm. 
 
 When infants are affected with malaria, decoction of leaves is used to bath.  
The smoke of the burning plant is also used for this purpose. 
 
 Ash obtained by burning the leaves of Aerva Lanata, after removing impurities 
when rubbed on the lower back gives relief from back pain. 
 
 Fresh leaves of Aerva Lanata are taken and crushed to apply on injuries or 
wounds, as it cures inflammation and reduces pain. 
 
 Leaves of Aerva Lanata are powdered and used as a medicine for Diabetics.  
The powder can be stored and taken two times a day.  It helps in controlling 
the sugar level in blood. 
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 Leaf-sap is used for eye problems.Infusion of aerva Lanata is used to treat 
Diarrhea, Inflammation and also can be used during Childbirth. 
 
 
OTHER PREPARATION WHICH CONTAINS CHIRUPEELAI: 
 
1. CHIRUPEELAI VER KUDINEER 
 
Indication   -kalladaippu 
 
          -Uyir kakkum Siddha maruthuvam 
    
2. KALLADAIPPU KUDINEER 
 
Dose  : ulakkalau 
Indication : kalladiappu 
-Yugi muni vaithiya kaviyam 
 
3. RAJA SINTHAMANI ENNAI 
 
Dose  : ¼-1/2 palam 2 times  
Indication  :  Megavayu  
-kannusamy parambarai vaithiyam  
       
 
 
4. KALLADAIPPU MARUNTHI 
 
Indication :  Kalladaippu  
Duration  : 3 days  
-Sarabaenthirar vaithiya muraiga  
Pitharogachigichai 
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5. CHIRUPEELAI SAMOOLA KUDINEER 
 
Indication  : kalladaippu  
-Gunapadam – mooligai 
 
6. THIRACHATHI CHOORANAM 
 
Dose   : Thirikadi 2 times 
Indication  : neerkaduppu, neererichal, neerkattu 
Duration  : 20 days  
- Kannusamy paramparai vaithiyam  
 
7. KALLUDAI KUDORI MATHIRAI 
 
Dose   : ulunthu size 2 times a day 
Indication  : kalladaippu  
 
- Siddha vaithiya thirattu. 
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3.1.2 BOTANICAL ASPECT: 
 
Botanical Name - Aerva lanata 
 
TAXONOMICAL CLASSIFICATION 
 
Division   - Spermatophyta 
Subdivision   - Angiosperma 
 Class    - Dicotyledonae  
Subclass   - Monochlamydeae  
Series    - Curvembryeae 
Family    - Amarantaceae 
 Genus    - Aerva 
 Species   - Lanata 
 
HABITAT: 
   
 Tropical, cosmopolitan in distribution found all over tropical India as a 
common weed in fields and waste places.  It also found Africa, Indomalaysia, and 
Arabia.  
 
HABIT: 
 
 Herbs (or) under shrubs 
 Erect (or) prostrate  
Tomentose herb  
 Branches woolly. 
 
 
LEAVES: 
  
 Simple, alternate, elliptic, obovate, pubescent above white woolly beneath-
upto 1” Long. 
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INFLORECENCE: 
 
 Spike, axillary less than 0.5 long. 
 
FLOWERS: 
  
Bisexual or polygamous, minute in small dense greenish white heads or 
spikes.  Bracteate and 2 small bracteoles present. 
 
PERIANTH: 
 
 5 petals, calycine in nature, membranous, the lobes are equal. 
 
ANDROECIUM: 
 
 5 stamens, filaments subulate, connate with interposed linear staminodes in a 
hypogenous cup, anthers 2 celled. 
 
GYNOEXIUM: 
 
 2 carpels, syncarpous. The ovary unilocular, superior, ovule, pendulous from a 
long basal funicle style – simple, stigma – 2. 
 
FRUIT  
 
A membranous utricle 
 
SEED: 
 
 Inverse testa coriaceous, embryo annular surrounds the floury albumen, 
cotyledons linear, radical superior.  
- Flora of presidency of madras vol II JS Gamble. 
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DESCRIPTION: 
 
 MACROSCOPIC 
Root - Tap-root, laterally branched, cylindrical, up to 0.8 cm. in thickness and 
about 25 cm. long pieces, externally light brown and rough but cut surface 
white and smooth; fracture fibrous and hard. 
 
       Stem - Nearly cylindrical, branching alternate, external surface shows slight 
ridges and              furrows, hairy and light brown in colour; cut surface white; 
fracture granular. 
 
Leaf - Simple, opposite, alternate, shortly petiolate, lamina 2.0 to 2.5 cm. long 
and 1.0 to 1.6 cm.broad, elliptic-orbicular or ovate, acute, reticulate veined, 
margin entire, densely pubescent on both surfaces. 
 
Flower - Minute cluster as axillary spike; greenish-white; perianth 5, 
bracteolate; actinomorphic,bisexual; stamen 5, opposite to perianth, anthers 2 
lobed; stigma bifid, superior ovary, unilocular with campylotropous ovule.49 
 
Fruit - A greenish, roundish, compressed membranous, utricle or 
circumscissile capsule with a coriaceous upper part or lid and containing a 
single seed. 
 
Seed - Seed minute, 0.5 to 0.7 cm. in dia., black, polished, lenticular; taste 
pungent. 
 
MICROSCOPIC 
Root - Shows 5 to 7 layers of cork cells, upper 2 or 3 layers filled with 
brownish content; 
secondary cortex a wide zone consisting of circular to oval, elongated, thin 
walled parenchymatous cells, most of the cells containing rosette crystals of 
calcium oxalate; endodermis not distinct;pericycle present in the form of 
interrupted ring of pericyclic fibres; anomalous secondary growth present; 
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secondary xylem and phloem tissues in form of 3 or 4 alternating rings; 
medullary bundles present; phloem consisting of sieve tubes, companion cells 
and phloem parenchyma; xylem consists of vessels, tracheids, fibres and 
xylem parenchyma; vessels circular to oval having simple pits; pith cells 
circular in shape containing rosette crystals of calcium oxalate. 
 
Stem - Shows slightly wavy outline, corresponding to ridges and furrows; 
epidermis single layered covered with thick cuticle; trichomes multicellular, 
end cells pointed or vesicular, warty and thick walled; cortex 6 or 7 layers 
with 3 or 4 layers below ridges being collenchymatous and 3 or 4 layers below 
furrows chlorenchymatous; rest of the cells oval to elongated, elliptical, thin 
walled and parenchymatous, with a few cells containing rosette crystals of 
calcium oxalate; endodermis single layered; pericycle present in the form of a 
ring, single or groups of 2 to 4 fibres; anomalous secondary growth present; 
vascular bundles arranged in 2 or 3 rings showing included phloem alternating 
with parenchymatous tissue; phloem consists of sieve tubes, companion cells 
and phloem parenchyma; xylem composed of vessels, tracheids, wood fibres 
and xylem parenchyma;vessels round to oval having simple pits; pith wide 
consisting of circular to polygonal havingintercellular spaces, rosette crystals 
of calcium oxalate present in this region. 
 
Leaf 
 
Petiole - Shows single layered epidermis covered with cuticle; trichomes 
multicellular present on both surfaces; cortex consisting of 2 or 3 layers, upper 
collenchymatous and lower parenchymatous; vascular bundle collateral and 3 
in number; rosette crystals of calcium oxalate present in cortical cells. 
 
Midrib - Epidermis, cuticle and trichomes, similar to those in petiole; cortex 5 
to 7 layers, upper 3 collenchymatous and lower 3 or 4 circular, thin walled and 
parenchymatous; vascular bundles 3 in number, 2 accessory and one middle; 
xylem towards the upper and phloem towards lower epidermis; rosette crystals 
of calcium oxalate present in cortical region. 
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Lamina - Epidermis, cuticle and trichomes similar as in petiole and midrib; 
palisade 1 or 2 layers;spongy parenchyma 3 to 5 layers composed of thin 
walled parenchymatous cells with intercellular spaces, a few rosette crystals of 
calcium oxalate present in spongy parenchyma; anomocytic stomata present 
on both surfaces; palisade ratio 2 or 3; stomatal index on upper surface 12 to 
15 and on lower surface 16 to 18; vein -islet number 4 or 5 per square mm                                        
                                                                           
 - The Siddha parmacopia ofIndia part I  
 
CHEMICAL CONSTITUENTS: 
  
 Plants contains four flavonoid,glycosides (I, II, III and IV) tannin which 
comprises β sitosteryl palmitate,  α amyrin, β sitosterol and its glucoside betulin, 
alkaloid canthin -6-one and β –carboline. 
 
- Medicinal plants of india volume -2 tamilnadu  
 
CONSTITUENTS: 
 
 β sito sterol, β sito sterol palmitate, campesterol, stigma sterol, stigma sterol 
acetate, daucosterol, ergosterol, a-amyrln, β amyrln, lupeol,betulin,olean-12-en-2foic 
acid, 16-dioxymethyl ester, hentriacontane, chrysin, 3 glo flavones, 4 methoxy, 3 glo 
3 methoxy flavones, kaemferol- 3 galactoside, kaemferol -3-rhammno galacto side 
aeruine,methylaeruine, aervoside, aervolomine, free sugars-fructose, galactose, 
rhamnose and 3G sucrose. 
 
- The Siddha pharmacopeia of india part I 
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USES: 
 
 Aerva Lanata is antimicrobial.  It helps is fighting against pathogens.  It 
protects both the skin and the body from pathogens. 
 
 Aerva Lanata is diuretic which helps in promoting the production of urine, 
effective in urethral problems, lithiasis and gonorrhea. 
 
 Aerva Lanata acts as a demulcent which helps in getting relief from pain and 
inflammation. 
 
 Aerva Lanata is anthelmintic which helps in destroying parasitic worms and 
reducing sores and injuries on the skin. 
 
 Aerva Lanata acts as an astringent thereby helping in reducing bleeding in 
piles.  It is also used as a treatment for diarrhea and hemorrhages. 
 
 Aerva Lanata stem acts as an antioxidant which helps in balancing the free 
radicals. 
 
 Aerva Lanata us lithontriptic and antilithic which gives the plant the power to 
destroy stones in kidneys and bladder. 
 
 Aerva Lanata behaves as a medicinal tonic. 
 
 Aerva Lanata is also known for increasing memory power. 
 
 Aerva Lanata is also used to treat headache, abdomen and digestion problems.  
It is effective for neck and back pain, fever, urine problems and also regulates 
body metabolism. 
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 Aerva Lanata is considered to be effective for hepatitis and inflammation of 
the liver.  It is a good remedy for strangury, i.e condition of painful or frequent 
urination. 
 
 Aerva Lanata is also used for treatment of many health problems like Anemia, 
Alzheimer, Cholesterol, lung problems, bone problems and also blood 
circulation. 
 
LATERAL RESEARCH OF AERVALANATA LINN: 
 
 The aqueous extract of aervalanata was evaluated for antiurolithiatic activity 
in male albino wistarrats.  The aqueous extracts of aevalanata were safe orally and 
exhibited.  No gross behavioral changes in the rats in hyper calculi animals, the 
oxalate, and calcium and phosphate excretion grossly increased. 
 
International journal of pharmaceutical science review and research. 
www.globlare search online.net 
int.J.pharm.sci rev.res.17 (2) 2012  
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3.2TRIBULUS TERRESTRIS 
3.2.1 GUNAPADAM ASPECT 
 
ெந¯xசி – Nerunjil 
Tribulus terrestris 
 
OTHER NAME: 
 
 Thirikandam, Thirikandagam, Thirithandam, Nerunjiputhum, Asuvasatiram, 
Suvathattam, Gokandam, Kamarasi, Suvathukandam, Kittiram, Gondam, Sutham. 
 
VERNA CULARNAME: 
 
Assamese   – Gokshura, Gukhurkata. 
Bengali   – Gokkshura, Gokhuri. 
Gujarati   – Be tha gokharu mithogokharu. 
Kashmiri   – Michirkana, Pakhada. 
Marathi   – Gokharu, Sarate. 
Oriya    – Gukhura, Gokhyura. 
Panjabi   – Bhakhra, Gokhru. 
 
-The Siddha Pharmacopocia of India Part 1 
 
VERBACULAR NAME: 
 
English   – Small Caltrops 
                      Land Caltrops 
             Puncture Vine. 
Telugu   – Palleru. 
Sanskrit   - Gokshura, Svadamstra, Trikanta. 
Hindi    – Gokhru. 
Malayalam   – Nerunji.  
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Arab    – Khara-Khusk.                                       
Bengali   – Gokhuri. 
Kannada   – Negil-mullu, Neggilu, Sannana ggilu. 
English   – Small Caltrops. 
Gwalior Hindi   – chota gokhru. 
 
PART USED: 
 
Whole plant. 
fruit and root 
 
ORGANOLEPTIC CHARACTERS: 
 
Taste     – bitter, sweet 
Potency   – cool 
Biotransformation              – sweet. 
 
PROPERTIES: 
 
Cuvai     – Inippu, Tuvarppu. 
Gunam    – Noymai, Tinmai. 
Virium    – Tadpam. 
Pirivu     – Inippu.                                               
 
- The Siddha Pharmacopoeia of India Part 1  
THERAPATIC ACTION: 
 
PLANT AND DRIED SPINY FRUIT: 
  
Cooling, Diuretic, Tonic, Demulcent, Aphrodislac, Astringent. 
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STEM: 
Astringent. 
 
INFLORESCENCE: 
 
The flowers are 4- 10mm wide,with 5 lemon yellow paetals, 5 sepals, and 10 
stamens. In Sothern California it blooms from April through October.Where it is 
highly invasive in waste places and disturbed sites. 
 
FRUIT: 
 
 A week after each flower blooms it is followed by a fruit that easily falls apart 
into 5 nutletes (or) burns. 
 The nutlets are hard and bear 2-4 sharp spines 10 mm Long and 4-6 mm broad 
point-to-point. These nutlets strikingly resemble goats (or) bulls’ heads. 
 
GENERAL CHARACTERS: 
 
நல ெந¯xசில¢ நா¶uகிƬvசர{ைத 
வல ரமனைல மா²uகாz-ெமலியேல 
மாநில{தி} கலைட~© வாuகாத நƫகy 
§²ெம வாத« ேபாt. 
 
ேமகெவyைட நƫ²t வ ²திƬ ேதாட©z 
ேவகாதர தாகெவ~ப வyெடாழி­-ேபாக| 
தரxசின மதைல ெமாழி{ ைதயேல நல 
ெந¯xசிலதைன நிைன. 
 
- Gunapadam mooligai, 
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 Sottuneer, Suravaethumbal, Kalladaippu, Neeradaippu, Mudavayu, Vellai, 
Siruneererichal, Mukutram, Neervetkai, Vepum. 
 
MEDICINAL USES: 
 
  It is believed to be helpful in treating some cardiovascular conditions 
including angina, high blood pressure, high cholesterol, anemia and poor circulation.  
Digestive disorders that may benefit from the use of puncture vine include 
constipation and flatulence.  It is used in Chinese medicine as a liver tonic, and for 
food poisoning and overeating.  It is has many uses in the Ayurvedic tradition, 
including pacifying vata, as a diuretic and to treat disorders of the genitourinary 
system.  In other medical traditions, this herb is also used as a diuretic to treat 
hypertension and for angina pectoris.  It is believed by some to help prevent both 
oxalate and struvite kidney stones.  It is believed to have antiseptic and diuretic 
properties that can reduce the incidence of urinary tract infections.  It is also used as a 
treatment internally and externally for immune disorders, such as allergic skin 
conditions, eczema and psoriasis. 
 
OTHER PREPARATION WHICH CONTAINS NERUNJIL 
1. THIRIKANDATHI CHOORANAM 
Adjuvent (anupanam)  – Honey (or) Ghoat milk. 
Duration    – 7 days. 
Indication    – kidney stones. 
-Anubaa vithiya Deva ragasiyam.  
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2. NERUNJIL LEGIYAM. 
Dose     – 24 gm. 
Indication    – Siruneer erichal, Neerdaippu, Sathaiadaippu. 
-Gunapadam mooligai vaguppu. 
 
3. NEER – MALA KATTUKU. NERUNJIL CHOORANAM. 
Dose     – 5-10 kundri or   6.50 mg-1.3 gm.  
 Daily    - 2-3 times 
Adjuvent (Anupanam)  – Elaneer (or) Venneer. 
Indication    - Piramegam, Neeradaippu, Saihaiadaippu, Kalladaippu     
Kaikalerivu, Elumburiki, Kunmanoi. 
-Agathiyar Pallu 200 
4. KUMKUMA POO LEGIYAM. 
Dose    – 5 gm.    2 times. 
Indication  –Meganeer, Vellai, Vettai Neeradaippu, Neerkaduppu, 
Sathaiadaippu,       Kalladaippu, Madhumoothiram, Nerilizhu, Rakthapiramagam, 
Perumpadu, Kustam, kiranthi, Soolai, Kirukirupu, Kaikal eruvu, Pithavettai, Megam, 
Asthisuram, Araiyappu, maladu. 
-Pirana Rakshamirtha Sindhu.       Part 2. 
6. NILAPANAI CHOORANAM. 
Dose    – Thirikadi. 
Anupanam   – Milk. 
Indication   – Neerkaduppu, Vellai, Thathupalaveenam. 
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7. NEERMULI KUDINEER 
 
Dose    - 1/2 alakku 2 times a day 
Indication  - neerkattu, sobai 
 
 
 
8. MANDOORATHI AADI KUDINEER 
 
Dose    - ¼ alakku    
2-3 times a day 
Indication   - pandu, sobai, kamalai magotharam 
- Siddha vaithiya thirattu. 
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3.2.2 BOTANICAL ASPECT 
 
Botanical Name   – Tribulus terrestris. 
 
TAXONOMICAL CLASSIFICATION 
 
Kingdom    – Plantae(Plants). 
Subkingdom    – Tracheoblosta. (Vascular plants). 
Division    – Spermatophyta (Seed plants). 
Subdivision    – Angiospermae. 
Class     – Dicotyledonae. 
Subclass    – Polypetalae. 
Series     – Disciflorae. 
Order     – Geraniales. 
Family     – Zygophyllaceae. 
Genus     – Tribulus. 
Species    – Terrestris. 
 
- Benthem and Hooker. 
 
FAMILY 
 
 Genera 22, Species 160, Xero and halophytes of tropical and subtropical 
regions. 
 
GENUS 
 
A Genus of ascending (or) Prostrate herbs, Commonly known  as Caltrops, 
distributed in the tropics and warm temperature regions of the world. 
 
 
 
 
26 
 
 
HABITAT 
 
 It is native to warm temperature and tropical regions of the old world in 
Southern Europe, Southern Asia, throughout Africa and Australia. It can thrive even 
in desert climates and poor soil. 
 
LEAVES AND STEM 
 
 Stems branch from the crown and are densely hairy Leaves are opposite and 
pinnately compound. Densely hairy Leaflets are opposite and up to 1/8 inch 
(0.0032m) Long. 
 
MORPHOLOGICAL CHARACTERS 
 
 A Variable prostrate annual upto 90 cm in Length, commonly found 
throughout India.  The herb is a common weed, springing up everywhere soon after 
the first showers. The herb flowers and fruits almost throughout the year. Leaves 
paripinnate, Leaflets 5-8 pairs, subequal, oblong to linear oblong, flowers leaf 
opposed, solitary, pale yellow to yellow, flowering starts with in 20-35 days fruits 
globose spinous (or) tuberculate consisting if 5-12 woody cocci each with 2 pairs of 
hard, sharp, divaricate spines, one pair longer than the other, seeds. Several in each 
coccus with transverse partitions  between them. Fruits matures in 14 days after the 
formation of seeds, roots slender, cylindrical, fibrous 10-15cm long, light brown and 
faintly aromatic. 
 
-The wealth of India.  Vol X   
 
ACTION AND USES 
 
 Plant and dried spiny fruit are esteemed as cooling demulcent, diuretic, tonic 
and aphrodisiac. The diuretic properties if the plant, no doubt are due to the Large 
quantities of the nitrates present as well as the essential oil which occurs in the 
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seeds.The fruit and root are sweetish, cooling, tonic, fattening, aphrodisiac, 
alternative, Improve appetite, useful in strangury, urinary discharges, vesicular 
calculi, pruritis ani, alternative burning sensation, reduce inflammation, remove 
tridosha, cough, asthma, pain, cure skin, and heart disease, piles, leprosy. 
 
 The seeds are cooling, fattening, diuretic, aphrodisiac, removes inflammation 
urinary troubles, stones in bladder. 
-Nadkarni’s Indian Materia Medica.Vol-I  
 
DESCRIPTION 
 
A.MACRPSCOPIC 
 
 Drug consists of root, 7 to 8 cm Long and 0.3 to 7 cm in diameter, slender, 
cylindrical, fibrous, frequently branched bearing a number of small rootlets, tough, 
woody and yellow to light brown in colour, surface becomes rough due to presence of 
small nodules, fracture fibrous, odour, aromatic, taste sweetish and astrigyent. 
 
MICROSCOPIC 
 Transverse section of primary root show a Layer of epidermis followed by 4 
(or)5 Layers of thin walled parenchymatous cortex, endodermis distinct, pericycle 
enclosing diarch stele, in mature root, cork 4 to 6 Layered cork cambium single 
Layered followed by 6-14 Layers of thin walled paranchymatus cells with groups of 
fibres, distributed throughout, some secondary cortex cells show secondary wall 
formation and reticulate thickening, secondary phloem divided into two zones, outer 
zone characterized by presence of neumrous phlowm fibers with a few sieve tubes 
slightly collapsed, inner zone frequently paranchymatous  devoid of fibres, often 
showing sieve tubes and cambium cells, phloem rays distinct  a few cells get 
converted into fibres in outer region cambium 3 to 5 Layered wood composed of 
vessels, tracheids parenchyma and fibres and traversed by medulary rays, vessels 
scattered arranged in singles or doubles towards inner side in groups of three (or) four 
on outer side having bordered pits, tracheids Long narrows with simple pits xylem 
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parenchyma rectangular (or) slightly enlongated with simple pits and reticulate 
thickening a few xylem fibres, medullary rays, hetrogenous 1 to 4 cells wide starch 
grains and rosette crystals of calcium oxalate present in secondary cortex phloem and 
medullary rays cells, a few prismatic crystals also present in xylem ray cells. 
                                                                        -The Siddha Pharmacopia of India  Part I 
CONSTITUENTS 
Diogenin, Hecogenin, Gitogenin, Tiyogenin, Neotigogenin, Stiymasterol, βsitoserol 
and Campesterol. 
-The Siddha Pharmacopia of India Part I 
The fruit are regared as cooling, diuretic, tonic and aphrodistic, and are used in 
painful micturition, calculus affection, urinary disorders and impotence. 
 In Southern India, the fruit is highly valved as a diuretic, In many cases where 
this has been tried the result was quite perceptible in the increase of urinary secretion.  
-Indian Medicinal plants Part 1 
The fruits are credited with diuretic and tonic properties and are used for the treatment 
calculus affections and painful micturition. 
-The Wealth of India. Vol-X. 
ACTION AND USES IN AYURVEDHA AND SIDDHA 
 Mathura rasam, Seetha veeryam, Mootralam, Vrishyam, Dipanam, Balakaram, 
Pustikaram, Prameham arsas, Kricharam, Swasakasam, hridrogam. 
ACTION AND USES IN UNANI: 
 Murakabul khuva, Diuretic, Aphrodisiac, Increase semen, removes stone, 
caused nugl in madda, in colic due to heat. 
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USES 
 Plant and dried spiny fruit are used in decoction (or) infusion in cases of 
spermatorrhoea, phosphaturia, diseases of the genitourinary system such as dysuria, 
gonorrhoea, gleet, chronic cystistis, calculus affections, urinary disorder incontinence 
of urine, gout, and impotence also in uterine disorder, after parturition and to ensure 
fecundity. 
- Indian Meteria Medica Vol I. 
The decoction (or) powder of seeds is given in calculi and sexual weakness. 
                                                           -Medicinal plants and folklores 
 Anti-ageing, Anti-bacterial, Anti-fungal,Anti-inflammatory 
 
 Anti-urolithiatic its juice/powder helps in urinary/kidney stone preventing and 
stone dissolving activities. 
 
 Anti-malarial 
 
 It improves libido function to normal rate and erectile function. 
 
 It helps to increase the number and motility of spermatozoa. 
 
 It helps in alleviating some symptoms associated with male menopause 
 
 It increase energy levels and provide health hormone function 
 
 It enhances muscle movement during exercise 
 
 It improves muscle growth and body strength 
 
 It increases in strength of contraction of the heart muscle 
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 It helps to reduce sodium and fluid retention 
 
 It is very useful and effective in treating Urinary Tract Infection and Urination 
problems 
 
 It helps to control high blood pressure 
 
 It helps to reduce in cholesterol  
 
 It reduces body heat 
 
 It relieves eye problems 
 
Sterols in Tribulus help to protect prostrate from swelling and protect prostrate 
from cancer 
                 
LATERAL RESEARCH OF TRIBULUS TERRESTRIS LINN 
 Evaluation of the aphrodisiac activity of Tribulus terrestris linn in sexually 
sluggish male albino rats.  J.Pharmacol Pharmacother 2012;3:43-7. 
A dose dependent Improvement in sexual behaviour was observed  with the 
Lyophihized aqueous extract of the dried fruits of tribulus terrestris (LAET) 
treatment.The enhancement of sexual behaviour was more prominent on chronic 
administration of LAET.  Chronic administration of LAET produce significant 
increase in serum testosterone levels with no significant effect on the sperm count 
finding of the present study validate the traditional use of T.Terrestris as a sexual 
enhancer in management of sexual dysfunction in males. 
Activity of certain fraction of Tribulus terrestris fruits against experimentally induced 
Urolithiasis in rats on subsequent fractionation of ethanol extract maximum activity 
was localised in the 10% aqueous methanol fraction.It provide significant protection 
against deposition of calculogenic material around the glass bead Implantation in 
albino rat 
31 
 
3.3 CRATAEVA MAGNA 
3.3.1GUNAPADAM ASPECT 
 
மாவலuக – MAVILINGAM  
Crataeva Magna 
 
OTHER NAME: 
 
 Mavilingu, kumaragam, varani 
 
MAVILINGAM OTHER NAME: 
 
 மாவலuக{தி} ேபƫ தைனேய வtக ேக¶ 
வாேனா வ திvசாகu 
ேகாவலuைகt மாரகன ேவத ©ப 
ணமான சா¯கா வக« மா 
ேயவலuைக ெய¸பலதிv ட¯மா 
ேய{தமா வ}னதா} தபனயா 
பாவலuைக மா|த{ைத யக{தியா 
அழகான மாவலuைக யாzைமயாேம 
 
Kumaragan, Suveatha Buspi, Sarugavigam, Elumbilathi Sudar, Vanni, Deepani, 
Manththai Agachi 
 
- Bogar nigandu 1200  
 
VERNACULAR NAME: 
 
English   - Three leaved caper 
Telugu   - Urumatti 
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Malayalam   - Nirvala 
Hindi    - Banan 
Sanskrit   - Pashungandha, Asmarighna 
Hindi    - Tapla Bilas 
Kanada   - Narumbela 
 
                                                             -   GUNAPADAM MOOLIGAI 
VERNACULAR NAME: 
 
English    -Three leaved caper holy garlicpear. 
Tamil     - Mavilinga Maram, Maralingam, Marilinga 
Kumarakam, Varani. 
Telugu    - Uskia, Urumatti. 
Malayalam   - Nirvala, Vilva-Patrani 
Hindi     - Tapla, Bilas, Barna 
Bengali   - Tikoshak, Textasak, Barun. 
Kanada   - Nirvala, Narumbeli, Bilapatri 
Punjabi   - Barna 
Marathi    - Ramala, Kumlakoomla, Varuna,Haravarna 
Burma    - Ka-Dat 
Gujarti    - Vaivarna vayavarna 
Cing     - Bilapatra 
Sanskrit   - Koomvaurna, ashmarighana, tapla, belpatra 
 
PART USED: 
 
 Leaves, bark, root 
 
ORGANOLEPTIC CHARACTERS: 
 
Taste     - Bitter 
Potency   - Heat 
Biotransformation             - Pungent 
33 
 
 
PROPERTIES: 
 
Cuvai   - Kaippu 
Gunam  - Ilaku varadci 
Virium  - Veppam 
Pirivu   - Karppu 
 
- The Siddha pharmacopeia of India part I 
ACTION: 
Stomachic 
Febrifuge 
Tonic  
 Rubefacient 
Laxative 
Lithotriptic 
                                                      -Gunapam mooligaivagupu 
Lithotriptic  
Laxative 
Stomachic 
Increase the biliary 
Secretion. 
-  Indian materia medica 
Anti periodic  
Tonic  
Demulcent  
- The wealth of India. 
 
Lithotriptic 
Liver stimulant 
Laxative 
Promotes appetite 
- Medicinal plants of india vol-II 
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Lithotriptic  
Diuretic  
Astringent  
Carminative  
Anthelminitic  
Stomachic  
Laxative  
Stimulant  
Expectorant  
Demulcent  
Anti periodic &Tonic 
-Indian medicinal plants vol-II (orient Longman) 
GENERAL CHARACTERISTICS: 
 
ரu கய} ேதாட| ெதாைலயாத வாத 
உர ெப² வடu கெளாழி­ – ர«u 
க¯மா வவய´u கzடxu கzணா 
ஒ¯ மாவலut ைர. 
 
It cures fever, unknown bite, snake bite, thiratha vali noi 
 
-  GUNAPADAM MOOLIGAI VAGPPU 
 
 
THERAPEUTIC USES: 
 
 Leaves decoction cures, fever, indigestion. The decoction of bark is internally 
administrated to cure diseases like renal calculi, dysuria, helminthiasis, inflammations 
and abscesses.  The decoction exhibits actions like carminative, laxative, thermogenic, 
diuretic, lithontriptic, expectorant and demulcent.  The leaf and stem bark have been 
evaluated for their antioxidant activity and inhibition of key enzymes relevant to 
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hyperglycemia.  The leaves of Crataeva magna are used in traditional medicine for the 
treatment of various kinds of wounds. 
 
OTHER PREPARATION WHICH CONTAINS MAVILNGU: 
 
VARUNATHI KIRUTHAM 
 
Indication   : Kidney stones, dysuria 
-Agnivasarin agasamgithai part 3 
MAVILINGU KUDINEER 
 
Indication  : kidney stone. 
-Valam tharum thavarangal part 5 
MAVILINGU CHOORANAM 
 
Dose   : 1 gm per day 
Indication   : kidney stone, fever, ulcer 
 
- Kosaii anubava vaithiya bramma ragasiyam 
 
AYAKANTHATHI KULIGAI 
 
Dosage   : 1 kuligai (pakkalavu) 
Indication   : jaundice 
 
- Agathiyar 2000 part 3 
 
VATHA SURA KUDINEER 
 
Indication  - Vatha suram, nadukku vatham. 
 
- Siddha vaithiya thirattu. 
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3.3.2 BOTANICAL ASPECT 
 
Botanical Name   –  Crataeva magna 
 
TAXONOMICAL  CLASSIFICATION 
 
KINGDOM  : Plant kingdom 
CLASS  : Dicotyledons 
SUBCLASS  : Polypetalae 
SERIES  : Thalamiflorae 
ORDER  : Parietales 
FAMILY  : Capparaceae 
GENUS  : Crataeva 
SPECIES  : Magna 
 
HABITAT: 
 
 Tropical, cosmopolitan, commonly found in Tamilnadu, central India, Bengal, 
Assam, Malabar and tropical Africa 
 
HABIT: 
  
A moderate sized deciduous tree with much branches and grey bark. 
 
 
ROOT: 
  
Long tap-root. 
 
STEM: 
 Wood, branched with long horizontal wrinkles, shiny, yellowish white, 
moderately hard, smooth and close grained. 
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LEAVES: 
  
Long petals, trifoliate, exstipulate, leaflets ovate (or) ovate lanceolate pale 
beneath upper surface is thin and dark green. 
 
INFLORESCENCE: 
  
Corymb. 
 
FLOWERS: 
 
 White in colour, pedicellate, ebracteate, bisexual, actinomorphic, hypogynous, 
greenish yellow (or) white with red stamens. 
 
CALYX: 
  
 Four sepals, deciduous. 
 
COROLLA: 
 
 Four petals, polypetalous, ovate, long clawed petals. 
  
ANDROECIUM: 
 
 Stamens numerous, free, adnate to the base of GYNOPHORE. 
 
GYNOECIUM: 
 
 Bicarpellary, syncarpous, sessile stigma, ovary superior, 1-celled, raised on 
long gynophores, placentation parietal many ovules. 
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FRUIT: 
 
 Berry, many seeded. 
SEED: 
 
 Woody, non-endospermic. 
 
PHYTO CHEMISTRY: 
 
Bark contains  - Saponin tannin. 
   
-  The wealth of India  
 
Root contains  - Triterpene alcohol. 
 
THERPEUTIC USES: 
 
 Bark of the crataeva tree taken with buttermilk cures stone in the bladder, 
megam veneral affections. 
-Tamil-English dictionary of medicine volume V 
  
 Bark of the crataeva given in calculi and other urinary tract infections. 
 
 Mavilingam bark, leaf and root used in urinary calculi ulcer, skin eruptions, 
vatha diseases, utricaria, snake bite, fever. 
 
 Varuna bark used in urinary calculi headache, carcinoma, cardiac diseases, 
gout, disorders of blood, rheumatic arthritis, worm infestations, gastritis, 
abdominal disorders. 
- Medicinal plants of India volume II 
 
 Bark is used in urinary disorders and calculous affections, dropsy combained 
with tribulus terrestris. 
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 The compound powder is given in calculus, ascites, and chronic enlargements 
of glands as liver, spleen and in affections of the bladder and uterus. 
 
 Fresh leaves and roots are mixed with coconut juice and ghee is given in 
rheumatism. 
 
 Paste of the leaves is applied to soles of the feet to rheumatism. 
 
 Paste of the leaves is applied to soles of the feet to relieve swelling and 
burning sensation. 
- Flora of British India part I.. 
 
 Crataeva used as lithotriptic action in renal calculi. Bark is especially useful in 
urinary complaints such as kidney and bladder stones 
 
- Materia medica of india and their therapeutics  
 
 Compound decoction contains its root bark and leaves and small calotropis 
bark, ginger, carbonate of potash, honey and water is very useful in urinary 
tract infections and calculi. 
 
 2 ounces of bark decoction three times daily as a good antiperiodic and tonic. 
 
 Bark is also used in snake bite 
 
                                                                    -.Indian material medica 
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DESCRIPTION 
 
MACROSCOPIC 
Thickness of bark varies, usually 1 to 1.5 cm. according to the age and portion of the 
plant 
from where the bark is removed; outer surface, greyish to greyish-brown with ash-
grey patches; at places, surface rough due to a number of lenticels, shallow fissures 
and a few vertical or 
longitudinal ridges; inner surface smooth and creamy white in colour; fracture tough 
and short; 
odour indistinct; taste slightly bitter 
 
MICROSCOPIC: 
 
Transverse section of mature stem bark shows an outer cork composed of thin 
walled rectangular and tangentially elongated cells, phellogen single layered with thin 
walled tangentially elongated cells followed by a wide secondary cortex, consisting of 
thin walled, polygonal to tangentially elongated cells with a number of starch grains, 
starch grains mostly simple, occasionally compound with 2 or 3 components also 
present large number of stone cells in groups of two or more found scattered in 
secondary cortex single stone cells not very common stone cells vary in size and 
shape being circular to rectangular or elongated with pits and striation on their walls, 
stone cells distributed somewhat in concentric bands in phloem comparatively a wide 
zone, consisting of sieve tubes, companion cells, parenchyma and groups of stone 
cells, alternating with medullary rays sieve elements found compressed forming 
certatenchyma in outer phloem region, where as in inner region of phloem, intact, 
medullary rays mostly multiseriate composed of thin-walled, radially elongated cells, 
tangentially elongated towards outer periphery, a number of starch grains similar to 
secondary cortex also present in phloem and ray cells, few rhomboidal crystals of 
calcium oxalate also found in the region. 
 
- The Siddha pharmacopia of India part I. 
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CONSTITUENTS: 
 
 Cadabacaine, cadabacine diacetate (-) catechin, (-) epicatechin-5-glucoside, (-) 
epiafzelechin, isothicyanate glusoside glucocapparin, taraxasterol, lupeol, 3-epilupeol, 
lupeolacetate, diogenim, friedelin, betulinic acid, ceryl alcohol and spinasterol acetate.                         
 
 
 
 
 
LATERAL RESEARCH OF CRATAEVA MAGNA: 
 
 Free radical scavenging activity, wound healing activity and estimation of 
phenolic flavonoid and proanthocyanide contents of the plane crateva magna. 
 
- Asian journal of pharmaceutical and clinical 
research vol 5 supp 3 2012. 
 
Effect of crataeva magna in experimental urolithiasis oral administration of 
crataeva magna bark decoction on calcium oxalate lithiasis has been studied in rats 
the increased deposition of stone forming constituents in kidney of calculogenic rats 
was lowered with decoction administration.  The increased urinary excretion along 
with lowered magnesium excretion found in stone forming rats was partially reversed 
by decoction treatment. 
 
Journal of ethno pharmacology vol-28 Issue march 
1990 
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3.4 PAVONIA ODARATA 
3.4.1 GUNAPADAM ASPECT 
 
ேபரா«y – PERAMUTTI 
Pavoniaodarata 
 
OTHER NAME: 
 
Tamil     – Peraamutti, Kastoori venda 
English    – Fragrant Sticky Mallow 
Ayurvedic              – Vaalaka, Baalaka, Baala, Barhishtha, Hrivera, Ambu, Jala, 
Nira, Paya, Toya, Udichya, Vaari, Muurdhaja, Sugandhbaalaa(also equated with 
Valeriana Jatamansi). In the South, Celus vettiveroides is equated with Baalaka. 
 
Other Name: 
  
 ேபரா«y ேபƫதைனேய ©கலtேக¶ 
  ேபரான மகாபலா வ¯ஷ©ப 
 தாரா«y{ த¯வா{தி யாஷகா 
  மி²{தா வாச ேதவtக பதாப தாப 
 ேபரா«y ய²¢ பலா ய¯வேயா வலி 
  ெயளதான அத ய´{¢ ேநானா சன 
 யார«y யuக{தி} தாப ேபாtகி 
  யாzைமயா ேபரா«y நாமமாேம. 
-Bogar Nigandu -1200 
 
 Mahapala, Varusapuspi, Tharuvathi, yasakasu, Miruthavancha devi, Kapitha, 
Pithasta, Iruthupala, Iruvayovalli, Asthakayurthunonasani, Angaththin thabampokki. 
 
 
43 
 
VERRNACULAR NAME: 
 
Hindi  -  bala,sugandha-bala, sugandhabala 
 
Kannada        -  bala raakshasi, bala rakkasi, bala-rakkasi-gida, balaraakshi         
gida,     balarakkasi, balarakkasi gida, balarakkasigida, balarakshasi, 
kareebaalada beru, madivaala, mudivaala, mudivala, peramuti beru 
 
Malayalam     -  iruveli, kuruntotti 
 
Marathi - kaalaavaala, kala-vala, kalavala, randodaki, sugandhabala, 
sughandabala 
 
Sanskrit  - ambu, ambunamaka, bala, balaka, barhishtha, harivera, hribera, 
hrivela, hrivera, kachamoda, keshanama, keshanamaka, keshya, 
kuntala, kuntaloshira, lalanapriya, toya, udichya, vajra, vala, valaka, 
valakah, valakam, varapinga, vari, varida,varinamaka 
 
Tamil   - anantai, anantavariti, anantavariti, anantavariticceti, antai, 
antaiyitan, arttavacceti, arttavam, ataiyalavan, avibattam, avipatam, avipattam, 
cakapita, carapantini, centotti, cukantapala, cunkattintakampokki, 
curiyamantiram, curiyarkkam, cutcayekavalli, cuvacakam, cuvaccalam, 
cuvacitam,cuvacitamutti, cuveccam, erunti, irutupala, karapattini, 
kayotalankam, kontulankam, kuruvicci, kuruvinci, makapala3, makapalam, 
makapela, malaittarikam, miruturoki, nattukkantam, pala, palututainetti, 
paramutti, paramutty, paratakam, pataippariyan, pattakam, pera muttiver, 
peraamutti,peramootie vayr, peramutiver, peramutti, peramutti, 
perunkuruntotti, pitaputpi, pitaputpi, rutupala, suvesagam, taramutti, 
tavarattiyali, totikam,totikamutticceti, totipela, totippari, totipparicceti, 
tuvaratini, vantirecceti, vantiyam, vantiyam, varantiyam, vataiyavalan, 
vattiracuram, vilivilanki, yokavalli 
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Telugu  -  chirubenda, chitlebunda, chitti benda, chittibenda, cittibenda, 
erra-kuti, errakooti, errakuti, ettakuti, ,muthupalaagamu, muttaavapulagam,  
muttavapulagamu, mutthava pulagam chettu, muttupalagamu, 
pudubodapu, theegabenda, thigebenda, tiga benda, tigebenda 
 
Tibetan  - ba-la-ka 
 
 
PART USED: 
 
Whole plant 
. 
ORGANOLEPTIC CHARACTERS: 
  
 Taste                                      - bitter                          
Potency                - hot   
           Biotransformation                   -sweet 
 
ACTION: 
  
 Cooling 
Carminative 
Diuretic 
Diaphoratic 
 
PLANT: 
          
 Anti- inflammatory 
Spasmolytic 
 
USES: 
  
 Rheumatic affections 
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ROOT: 
 
 Stomachic 
Astringent  
Demulcent 
USES: 
 
 Dysentery 
Haemorrhages 
Ulcers 
Bleeding disorders 
 
GENERAL CHARACTERS: 
 
வாதர தாக மதைல கணமா|த 
சீதர ப{தாமனv ெச~பணu – ஓ¢நபா 
ேசரா«y ேகx ெசய மடமயேல 
ேபரா«y உைர{¢ ேப. 
 
-Gunapadam mooligai 
 
Valisuram, Neervaetkai, Mantham, Kanam, Iyya suram, Thekkutram. 
 
MEDICINAL USES: 
 
                                 2 teaspoons of fresh juice of the leaves of Pavonia Odarata along 
with black pepper for treating dysentery of babies. 
                                  These leaves also have emollient properties and the fresh juice 
extracted from the leaves of Sugandha Bala herb was used for soothing and softening 
the skin. 
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OTHER PREPARATION WHICH CONTAINS PERAMUTTI 
VER: 
 
1. PERAMUTTI KUDINEER 
 
Dose             -1/4 padi 
Indication   - kalladaippu 
                Neerkaduppu 
                Neereriu  
                              
-Molligaimarmam . 
2. ATTAMOOLA KUDINER 
 
Indication  -fever 
 
                               -Ealiya vaithiya muraigal. 
3. SAGAMATHI GIRUTHAM 
 
Dose   - 1-1/2 theakkarandi  
                2 times 
Indication  - all type of rheumatic disease 
 
4. VALI VEPPU KUDINEER 
 
Indication  - Vatha Suram, Nadukkuvatham 
 
5. MAHAVILVA KARPA LEGIYUM 
 
Dose   -    Pakkalau (2 times a day) 45 days 
Indication - Visa Pandu, Sakthikunmam, Rakthapitham, Maradaippu, 
Kirani, Kulaiervu, Ruthravaiyu, Asthisuram, Mayakkam, 
Kirukirupu, Soolai. 
 
47 
 
3.4.2 BOTANICAL ASPECT 
 
Botanical Name   - Pavoniaodarata 
 
TAXONOMYICAL CLASSIFICATION 
 
Kingdom  - Plant Kingdom 
Class   - Dicotyledons 
Subclass  - Polypetalae 
Series   - Thalami florae 
Order   - Malvales 
Family   - Malvaceae 
Genus   - Pavonia 
Speries  - Odorata 
 
HABIT: 
  
Sub shrub up to 1m 
 
FLOWER 
 
In axillary, solitary, pink (or) white, flowering throughout the year. 
 
FRUIT 
 
A globose schizocarp, pubescent, seed 1 per mericarp, reniform, fruiting 
throughout the year. 
 
LEAF 
 
Alternate, simple (or) palmate, ovate. 
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HABITAT 
 
 Found in open woods and waste places in the Deccan peninsula parts of West 
Bengal, Bihar, Orissa, Uttar Pradesh, and Rajasthan also cultivate in garden. 
 
USES 
 
 Plant – preparation internally in skin eruptions and disease due to vitiated 
blood. In the form of medicated Ghirta (purified butter) it was prescribed in phthisis, 
asthma, emaciation, debility and neurological disorders. 
 
 Externally a paste of the herb was applied in erysipelas. During 16th century 
the drug entered into a number of compound preparations for fever of various origins, 
diarrhea, dysentery, arthritis, gout, cough, and asthma.Preparation of the root with 
aeglemarmeloes is useful in dysentery the root used for their refrigerant, antipyretic, 
stomachic and astringent properties. 
 
 Pavonia odarata(Sugandha Bala) essential oil is used as an important 
ingredient in cosmetics, shampoos, conditioners, pomades, hair tonics, massage oils 
for rheumatism and much more.  You can use this essential oil as gentle massaging oil 
after blending it with mild carrier oils like olive oil for treating digestive disorders, 
pain, inflammation, infections, skin problems and rheumatism.  Adding 2 to 3 drops 
of this oil to your bath tub can also grant you similar health benefits and alleviate 
pain.  Using it in diffusers, air fresheners, burners and vaporizes can protect you from 
the invasion of harmful micro- organisms 
 
ACTIVE PRINCIPLES   
 
 Root gave an essential oil containing isovaleric acid, isovalealdehyde 
aromadendrene, pavonene, alphaterpinene, azulene and pavonenal.Biological activity 
of the plant was found to be spasmolytic, anti protozoal and antipyretic. 
-Indian herbal remedies western therapy ayuredic and other.  
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LATERAL RESEARCH OF PAVONIA ODARATA LINN 
 
 Antimicrobial and anti-inflammatory activity of bioactive. Components of 
pavonia odarata root.  CHCL3 root extract of pavania odarata has better anti microbial 
activity compare to ethyl acetate and methanol extracts.  The anti inflammatory effect 
of ethyl acetate and chloroform fractions may have related to different chemical 
composition presented in the plant nature which has proved as anti inflammatory 
activity compared with the standard drug. 
American journal of phytomedicine and clinical therapeutics.  www.ajpct.org  
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3.5 PHARMACEUTICAL REVIEW 
 
KASAYAM (SIDDHA ASPECT) 
 
OTHER NAME: 
 
 Marunthu Neer, Unner, Vaikudithidum Punal, Kudineer. 
 
PROCESS: 
 This is also called as medicinal water (or) decoction. 
 Dry (or) wet herbs are made in coarse powder and water is added in ratio of 
2:1, 4:1, 6:1,8:1, 16:1 (or) 24:1.  It is then boiled and filtered.  The filterate is known 
as KASAYAM . 
 
SHEIF LIFE: 
 3 hours (1 samam) 
 
SPECIAL METHOD: 
 
Thogai kudineer. 
                          Example: pancha moola kudineer. 
 
நƫ வைனயற ேமாதி நƬன தைறவா 
திƫ பxச ¬லt நƫ வைக ேக 
றி«t ககƬ டசேவƫ மணேவƫ 
லிைவ யவ¢ நƫ ப¯கிƫ. 
      (ேத.கƬச). 
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KASAYAM PREPARATION METHOD: 
  Kasayam prepare in following method the efficacy, purity and safety of 
kasayam increase. 
Use wide mouthed vessel – Always, while preparing Kashayam, use a wide mouthed 
vessel. This will help in early and easy evaporation of water and makes the process of 
boiling a lot quicker. 
Mild fire – To make kashayam, always use mild heat. Intense heat may cause 
charring of herbs inside the vessel. Slow transfer of herbal active principles into water 
is required for maximum efficacy. 
Size of herbs – The size of herbs should be neither too large nor too fine. Coarse 
powder of herbs is best to prepare good quality kashayam. 
Use only dry herbs - except for a few herbs, most of the herbs used in preparing 
kasayam are used in dry form only. 
Do not cover with lid – while making kasayam, the vessel should not be covered 
with lid.  If lid is covered, the boiled water will get condensed and will again fall back 
into the vessel.  We need to boil the herbs in open air. 
Continuously stir and watch – throughout the procedure, the herbs coarse powder 
should be continuously stirred and watched.  This will avoid charring of herbal 
powders. 
Proportion of herb and water and reduction – for any kasayam, generally herb is 
to water ratio is 1:4 or 1:8 
The kasayam should be boiled till the total water quantity in the vessel reduces to a 
quarter (1/4) 
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Take care while filtering – use a clean cloth to filter kasayam.  Filter the kasayam 
when it is still mild hot. 
Use it before 4 hours – once prepared kasayam should be used within 4 – 5 hours 
after preparation.  If it is kept for too much long time, then it may get spoilt. 
Do not reheat kasayam – once prepared kasayam should not be re-heated.  This may 
spoil the active herbal principles in the kasayam. 
Do not re-use the same herbs, once used for kasayam – the herbs used to prepare 
kasayam should be thrown out after preparation.  It should not be re-used. 
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Table no: 1 ANALYTICAL SPECIFICATIONS OF CURNA/CHOORNAM 
(FINE POWDER)/KVATHA CURNA/KUTINIR CHOORNAM 
(COARSE POWDER FOR DECOCTION) 
 
 
 
 
 
 
 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                              
 
 
Sl.No TESTS 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
 
Description 
Macroscopic, Microscopic 
Loss on drying at 105 C 
Total – ash 
Acid – insoluble ash 
Water-soluble extractive 
Alcohol – soluble extractive 
Particle size (80-100 mesh for Churna; 40-60 
mesh  for Kvatha churna) 
Identifications, TLC/HPTLC-with marker (wherever 
possible) 
Test for heavy/Toxic metals 
Lead 
Cadmium 
Mercury 
Arsenic 
Microbial contamination 
Total bacterial count 
Total fungal count 
Test for specific Pathogen 
E. coli 
Salmonella spp. 
S.aureus 
Pseudomonas aeruginosa 
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3.6 DISEASE REVIEW                                                            
3.6.1SIDDHA ASPECTS 
 
In Siddha system urinary disease are classified into 
 
1. Neerinai Perukkal Noi  
 
2. Neerinai Arukkal Noi 
 
In Siddha kalladippu disease is mentioned by yugi munivar in yugi vaidhya 
chinthamani 800.  It is one of the urinary diseases which come under Neerinai 
Arukkal Noi. 
 
VERUPEYAR (synonym): 
 
Ashmari rogam 
  
EYAL (Definition): 
 
தாென}ற ¬{திர{தி நறநறெவ}² 
தuகியேதாƫ ெபாெய§ மணதான~பா 
வாென}ற சிறிெதா¯ கலாவத~பா 
வளமாக வ|¢ வ¸ ேநாt தாேன. 
ஏென}ற அமƬ ேராக எ}ற ேபரா 
 
- AGASTIYAR GUNAVAGADAM  
 
According to Agastiyar Gunavagadam crystals which look like sand deposited in 
urine followed by small size stones which is excreted in urine and also sudden 
obstruction in flow of urine, pain in the base of penis in males and clitoris in females, 
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burning micturition, loin and groin pain, passing of small sand like stones along with 
urine are the features of this disease. 
 
IN JEEVARATCHAMIRTHM 
 
 Kalladaippu is defined as pain present in abdominal region.  Particularly 
around the umbilicus, fever, dysuria, urine smell like that of goat urine. 
 
NOI VARUM VAZHI (AETIOLOGY) 
                                          In Siddha system cause of this kalladaippu disease 
according to MAANMURUGIYAM are mentioned 
க¯நரடtக வைரவ அபட 
நƬய|தாtக சி² நரடtக 
வளேநா மி¯t «ணº ஒ¸tக« 
கைட~ ப{தித ேமக«த பல 
பண­ற எ¸மிைவ ய~பைடயாகt 
கலைட~ ெப}§u கபண வைள­ 
வளய¢ மறிைய ெயா மலா¢ 
க¯ெராu கல|¢ற நரடக{¢v 
சி²நƫt கழிº ெதா{த லா¢ 
அ}னைக கெலன{ திர¶ எ}ப 
                                   
                               The above poem describe that derangement in human blood, 
excessive indulgence in sexual activity, trama on tests, sexual pervertion, suppression 
of urine and semen. 
                               Inflammation of bladder, syphilis, stagnation of urine in urinary 
tract, dryness of semen causes the formation of stones.  Increase intake of food that 
cause flatulence. 
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IN SIDDHA MARUTHUVANGA CHURUKKAM: 
 
“நƬைன த¯{த ெசய} நƫகy ¢வார ©zணா 
பாƬ ச|¢ த}ன பz©² ேநாவதா 
ேநƬலu கய¯ காமிய நிvசய ேநாத  ெச­ 
பாƬ அபானவா­ பz©ற ேச¯ம}ேறா” 
“tகில த}ைன அடtகி} ர«லட} நƫகyடா 
பtகமா ைககா ச|¢ பாரமா வழியறu 
மிtகேமாƫ ேநா­zடா மி|தி பரேமக|தா} 
தtகேதாƫ ேபா¢மாகி} தƬ{தி வா­வ} ேற” 
 
                 The natural urges of our body are urine and semen suppression of excretion 
of urine or semen are one of the important causes for the production of stone in 
bladder. 
ACCORDING TO YUGI VAIDHYA CHINTHAAMANI 
Chronic mega noi (syphilitic disease) the semen will stagnate for a long time 
in the urinary tract so it will obstruct the urinary flow so urinary constituents will 
easily deposit on the urinary tract and form the stone. At that time vitiation of vatham 
and pitham these small stones become larger in size and block the urinary passage. 
 
கலuகிணேதாƫ தzணƫக {த ேபாt 
கெல²© மயƫ மz தா} கல|த}ன{தி 
அலuகினேதா ர}னuக அ¯|தலா´ 
மலuகிணேதாƫ மா~பzட ம¯|தா´ 
ம|த{தி வாவான பதாƫ{த| த}ைன 
¢லuகினேதாƫ ¯சித}னதி ைவ{தலா´ 
¯tகாt கலைட~© வ|¢ ேதா}². 
-YUGI VAIDHYA CHINTHAMANI 
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POTHU KURI KUNANGAL 
 
உ|தி த}ன§ அத} கீ ம¯uகி§ 
வைர நர ப{¢ ேநாº ேதா}ற 
சி²நƫ ெநறிய க´ர{ த~ப} 
«Ƭ{¢ «Ƭ{¢ நƫ வ |தித 
கல¢ வலகி நி}றி} சி²நƫ 
ெதள|தின மxச நிற{தி ெலா¸த 
எ§மிைவ கலைட ெபா¢ றி ெய}ப. 
 
Gradual (or) sudden obstruction to flow of urine, agonizing pain in the penis, colicy 
pain, radiating from loin to groin, lower abdomen, urethra, genitatia. If the calculus is 
irregular shape. It will burn and scanty micturation and hamaturia. 
 
NOI ENN (Classification) 
 
  In Siddha system various types of Kalladippu are mentioned. 
 
ACCORDING TO YUGI VAIDHYA CHINHAAMANI 
 
    Four types 
 
1. Valikalladaippu. 
      2. Azhal kalladaippu. 
      3. Iyya kalladaippu. 
      4. Mukkutra kalladaippu. 
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ACCORDING TO NOIVILAKKAM 
வள «த ¬}றி§ ேதா}றலா´ 
க¯நƫ த}ன ேதா}றலா´ 
கலைட நாவைக பெம} ெமாழிேய  
 
Four types  
 
1. Vali kalladaippu. 
2. Analaka kalladaippu. 
3. Iyya kalladaippu. 
4. Karuneer kalladaippu. 
ACCORDING TO SIDDAR ARUVAI MARUTHUVAM 
 Four types  
 
1. Vali kalladaippu. 
2.  Azhal kalladaippu. 
3. Iyya kalladaippu. 
4. Veneer kalladaippu. 
 
 ACCORDING TO NOIVILAKKAM 
KURI GUNANGAL-4 
VALI KALLADAIPPU 
 
படƫமிக~ பத பக க{த 
நuக உ|தி­u றி­ பைசத  
கசகீ வளெயா¯ கழல அ¸த 
சி²நƫ ¢ள{த எ}பº பறº 
வளய} கலைடt றிெயன ெமாழிேய. 
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Tongue biting, palpitation, shivering, crushing pain of the lower abdomen and genital 
organ, dribbling of urine, the stone are blackish red in colour. 
 
ANALKALLA DAIPPU 
 
yெடன நிƬய மிகெவ பத´ 
ேநாத´ அைலt கலைடt றிேய 
சிவ|¢u க²{¢ மxசளாகி­ 
ேசu¯ வவ கல¢ ேதா}². 
 
Burning micturition,dysuria the stone are reddish black (or) yellow in colour and 
passing small stones. 
 
IYYA KALLADAIPPU 
 
நƬயu {த திண{த ளƫத 
எ§மிைவ ஐயt கலைடt றிேய 
ெவ¶{¢ ேதனற மாகி­ ெமாளƫ|¢ 
ெப¯வ ºைட{தா ஐயt கலைட. 
                           
 Pricking pain, forceful pain with severe intensity when passing urine, fever with 
rigor, white (or) honey coloured, shining (or) laminate larger size stone expelled. 
 
KARUNEER KALLADAIPPU 
 
க¯நரyக கலி} வள சின|ெத¶|¢ 
வைரனள னவ அ¢தைன த{தலி} 
க¯நƫ கலைட ம¯வ  
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KURIGUNANGAL 
 
ACCORDING TO YUGI VAIDHYA CHINTHAAMANI 
 
VALI KALLADAIPPU 
 
Acute pain in lower abdomen, swelling in abdomen, urinary flow is 
uncontinuous so pain present in penis, sometime mucous discharge in urine, patient 
unable to sit. 
 
AZHAL KALLADAIPPU 
 
 Obstruction of urinary flow, burning sensation and acute pain in urethra, 
excretion of small red coloured stones. 
 
IYYA KALLADAIPPU 
 
 Severe pain present in umbilicus, pain radiating towards the thigh, burning 
micturation, excess sweating and small white colour stone sometimes comes with 
urine. 
 
MUKKUTRA KALLADAIPPU 
 
 It is also called Venneer Kalladaippu (or) Manarkalladaippu. 
 Pain in tip of urethra, irregular urinary output and small stone come along with 
urine and semen. 
IN AYURVEDA KALLADAIPPU 
Four types  
1. Vataja ashmari. 
2. Pittaja ashmari. 
3. Kaphaja ashmari. 
4. Sukraja ashmari. 
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VATAJA ASHMARI 
 The pain will be excruciating. The patient constantly under severe pain presses 
his umbilical region. 
 Burning sensation is experienced in the peinis, and while urination, belching 
and defecation become difficult and painful. 
 Hematuria may seen. 
 Ashmari are found to be a dusty colour, rough, uneven shape, etc. 
 In ayruveda texts the shape of the stone described as hard faceted and nodular 
like kadamba flower.  
 Resembles uric acid stone. 
PITTAJA ASHMARI 
 Sucking, drawing, burning sensation of pain experienced in the condition.   
 Stone is found to be reddish, yellowish black, like seed of the Bhallathaka fruit 
or like the color of the honey. 
 Resembles to calcium oxalate, uric acid and cystine stone. 
 Urine- color yellowish red. 
 Sometime chills, fever also associated. 
KAPHAJA ASMARI 
 Pain in the bladder region like that of “suchi birava”, like needle prick. 
 Have the pain but it is not sever as vataja type.  Kind of crushing pain, 
bursting in the organ which becomes cold and heavy.  May feel stiffness on 
that region. 
 Urine color is white. 
 Stone is white, glossy and attain to large size to that of hens egg.  And has the 
color of madhuka flower.Resembles to calcium phosphate stones. 
SUKRAJA ASMARI 
 It is seminal origin due to sudden or abrupt stoppage of sexual act or 
excessive coitus tends to discharge the semen and sediment in abnormal 
place.  Leads to formation of stone. 
 Associated with pain in the bladder, dysuria, swelling in the scrotum. 
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 (In anubhava vaidya deva ragasiyam.,roga nirnaya saram and jeeva ratchamirtham 
kalladaippu classified in to 5 types) 
 
MUKKUTRA VERUPADUGAL 
(Pathology) 
 
In siddha maruthuvam 
 
 During alternation in once diet and water intake vatha and pitha.Dhosa will 
alter (or) increase in the body it will affect the abana vayu. So urine will be stagnated 
in the urinary tract so salt deposit easily anywhere in the urinary tract and forms the 
stone. 
 
In Ayurvedha, 
The disease process can be explained in the following ways, 
 
1. Vadha dosha aggravated in urinary bladder.  The vadha has the qualities like 
rough the virtue of these qualities it dries up the locally available urine.  Pitha 
dhosa convert them into sarkara or gravels. 
2. Kapha dosha bind those gravels together to make a soft stone like structure. 
 
 
DIET AND LIFE STYLE 
 
WHAT CAN HAVE? 
 
 Increase fluid intake upto 2-3 liters per day. 
 Consume food rich vitamin A, Mg, etc 
 Limit salt intake. 
 Consume diet rich in fiber, etc. 
 Proper exercise and work management. 
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WHAT DON’T? 
 
 Avoid milk, ghee and other milk products. 
 Leafy vegetables like spinach, tomato, cauliflower, cabbage, peas, etc. 
 Avoid excess animal protein, red meat. 
 Getting exposed to heat. 
 Withholding physical urges like urine, stool, semen, etc. 
 Beer, chocolate, soft drinks, etc. 
 
YOGA FOR URINARY CALCULAI 
  
 It is advisable to practice yoga along with medicines to relieve the symptoms 
of calculai.  Some of the asana useful to reduce the conditions are, 
 
1. Dhanurasana  (bow pose) 
2. Pawanamuktasana (wind relieving pose) 
3. Uttana padasana (raised leg pose) 
4. Matsyasana (fish pose) 
5. Vajrasana 
6. Pranayama 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
Figure no:1  
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3.6.2 MODERN ASPECT 
 
Urolithiasis : 
 
 Urolithiasis (or) formation of Urinary Calculi at any level of the Urinary tract 
is a common condition. It comprises nephrolithiasis(the formation of kidney stones) 
 
Ureterolithiasis (the formation of stones in the ureter and cystolithiasis. (The 
formation of bladder stones). 
 
Urinary Calculi are worldwide in distribution but are particularly common in some 
geographic locates such as in parts of the United States, South Africa, India and 
South-East Asia. It is estimated that approximately 2% of the population experiences 
renal stone disease at sometime in their life with male-female ratio of 2.1. The peak 
incidence is observes in 2nd to 3rd decades of life. 
 
CAUSES 
 
 Decrease Urine Volume. 
 
 Inadequate Urine drainage which may lead to stasis. 
 
  50% of patients with calcium stones gave idiopatic hypercalciuria, without 
hypercalcaemia. 
 
 10% cases are associated with hypercalcaemia and hypercalciuria most 
commonly due to hyperparathyrodism (or) a detect in the bowel.(i.e. 
absorptive hypercalciuria) (or) in the kidney (i.e. renal hypercalciuria). 
 
 Infection of urinary tract with Urea splitting, organisms that produce Urease 
such as by species of Proteus, Streptococcus, Staphylcoccus, Klebsiella, 
Pseudomonous. 
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 Uricacid stones are formed frequently in case with hyperuricaemia and 
hyperuricosuria such as due to primary gout (or) secondary gout. 
 
 Acidic Urinary(below) PH and Low Urinary Volume. 
 
 Cystine stones are associated with Cystinuria due to genitically determined 
defect in the transport of cystine and other aminoacids across the 
cellmembrane of the renal tubules. 
 
 Decreased in Urinary Citrate Levels leading to deposition of Calcium. 
 
 Deficiency of Vitamin A and C 
 
 HYPEROXALATE 
       High dietary intake of the fruit and vegetable 
       Low Calcium diet. 
 
TYPES 
 
1. Calcium Stones – 75% 
Calcium Oxalate. 
Calcium Phosphate. 
 
2. Mixed (struvite) Stones-  15% 
 
3. Uric acid  Stones – 6% 
 
4. Cystine Stones – 2% 
 
5. Other type (xanthin calculi) - <2% 
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MORPHOLOGY OF STONES 
 
1. CALCIUM STONES 
 
Calcium stones are usually small(less than a centimeter). Ovoid, hard with 
granular rough surface. They are dark brown due to old blood pigments deposited in 
them as a result of repeated trama caused to the urinary tract by these sharp-edged 
stones. 
 
2. STRUVITE STONES 
 
Yellow –white (or) grey. They are trend to be soft and triable and irregular in 
shape. 
 
3. URIC ACID STONES  
 
Smooth, Yellowish-brown, hard and often multiple on cut section, they show 
laminated structures. 
 
4. CYSTINE STONE  
 
Small, rounded, smooth and often multiple. They are yellowish and waxy. 
 
SIGNS AND SYMPTONS  
 
 In the kidney fixed renal pain, (flank pain)is common. 
 
 In the ureter (according to Localisation of stone) 
 
 If in upper 1/3 of the ureter pain radiates to the perineum if the pelvic 
brim- pain radiates to the inner aspect of thigh. 
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 If present in middle 1/3 of ureter –pain radiates to the iliac fossa. 
 
 If the stone is Localised in the bladder neck (or) Urethra. 
-pain may presence as tip of penis. 
 
 Frequently of Urination. 
 
 Oliguria. 
 
 Dribbling of Urine. 
 
 Hematuria. 
PATHOGENESIS: 
 
 The mechanism of Calcium stone formation is explained on the basis of 
supersaturation of ions of forming the stone and the concentration of inhibitors 
in the urine most likely site where the crystal of Calcium Oxalate and /or 
Calcium Phosphate are precipitated  is the tubular lining (or) around some 
fragement of debris in the tubule acting as nidus of the stone. The stone grows, 
as more and more crystals are deposited around the nidus. A number of other 
predisposing factors contributing to formation of Calcium stones are alkaline 
Urinary PH decreased Urinary Volume and increased excreation of oxalate 
and uric acid. 
 
 The solubility of uric acid at PH of 7 is 200mg/dl while at PH of 5 is l5mg/dl. 
Thus as the urine becomes more acidic, the solubility of uric acid in urine 
decreases and precipitation of uric acid crystals increases favouring the 
formation of uricacid stones hyperuricosuria is the most important factor in the 
production of uricacid stone, while hyperureamia is found in about half the 
case. 
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 Excessive excretions of cystine stones are associated with cystinumia due to 
genetically determined defect which is least soluble of the naturally-occuring 
aminoacid leads to formation of crystals and eventually cystine calculi. 
 
COMPLICATION  
 
 Hydronephrosis. 
 
 Pyonephrosis. 
 
 Chronic unilateral (or) bilateral hydronephrosis produce other renal 
diseases. 
 
 Chronic renal failure 
 
 Hydrouretero nephrosis. 
 
 Chronic retention of urine. 
 
 Pyocystitis. 
 
DIAGNOSIS OF KIDNEY STONES: 
 Diagnosis of kidney stones requires a complete health history assessment and 
a physical exam.  Other tests include: 
 Blood tests for calcium, phosphorus, uric acid and electrolytes. 
 
 Blood urea nitrogen (BUN) and creatinine to assess kidney functioning. 
 
 Urinalysis to check for crystals, bacteria, blood and white cells. 
 
 Examination of passed stones to determine type. 
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The following tests can rule out obstruction: 
 
 Abdominal X-rays. 
 
 Intravenous pyelogram (IVP) 
 
 Retrograde pyelogram 
 
 Ultrasound of the kidney (this is the preferred study) 
 
 MRI  of the abdomen and kidneys 
 
 Abdominal CT scan. 
MANAGEMENT  
 
 Small stone Less than 5 mm (0.2inch) in diameter may pass spontaneously 
through urination within four weeks of the onset of symptoms but larger stones 5-
10mm(0.2 to 0.4 inch) in diameter the rate of spontaneous passage  decrease to less 
than 53% 50 dietary recommendation to minimize the formation of kidney stones 
include. 
 
 Increase total fluid intake to more than two litre per day of urine output. 
 
 Increasing citric acid intake, lemon juice is the richest natural source. 
 
 Moderate calcium intake. 
 
 Limiting sodium intake. 
 
 Avoidance of large dose of supplemental Vitamin C. 
 
 Limiting animal protein intake.Limiting consumption of cola soft drink 
because which contain phosphoric acid. 
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 Restriction of oxalate rich foods such as leaf,vegetables, soy products and 
chocolate. 
 
TREATMENT 
MEDICATION 
Pain relief may require narcotic medications.  The presence of infection requires 
treatment with antibiotics.  Other medications include: 
 Allopurinol for uric acid stones  
 Diuretics 
 Sodium bicarbonate or sodium citrate 
 Phosphorus solutions. 
LITHOTRIPSY 
 Extracorporeal shock wave lithotripsy uses sound waves to break up large 
stones so they can more easily pass down the ureters into your bladder.  This 
procedure can be uncomfortable and may require light anesthesia.  It can cause 
bruising on the abdomen and back and bleeding around the kidney and nearby organs. 
TUNNEL SURGERY (Percutaneous Nephrolithotomy): 
Stones are removed through a small incision in your back and may be needed 
when: 
 The stone causes obstruction and infection or is damaging the kidneys. 
 The stone has grown too large to pass 
 Pain cannot be controlled. 
URETEROSCOPY: 
 When a stone is stuck in the ureter or bladder, your doctor may use an 
instrument called a ureteroscope to remove it.  A small wire with a camera attached is 
inserted into the urethra and passed into the bladder.  A small cage is used to snag the 
stone and remove it.  The stone is then sent to the laboratory for analysis. 
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4.MATERIALS AND METHODS 
4.1 PREPARATION OF MAVILINGU KASAYAM 
DRUG SELECTION: 
 MAVILINGU KASAYAM has been selected from the Siddha literature 
Agasthiyar 2000 part 3. 
Ingredients of the drug are 
1. MAVILINGU VADAKU VER 
2. NERUNJIL VER 
3. CHIRUPEELAI VER 
4. PERAMUTTI VER 
COLLECTION OF THE RAW DRUG: 
1. Mavilingu vadaku ver : 
The raw material of crataeva magna root was identified and authenticated by 
PG Gunapadam Department, Govt Siddha Medical College Palayamkotttai 
Tamilnadu. 
 
2. Nerunjil ver : 
The raw material of tribulus terrestris root was identified and authenticated by 
PG Gunapadam Department, Govt Siddha Medical College Palayamkotttai 
Tamilnadu. 
 
3. Chirupeelai ver : 
The raw material of aervalanata root was identified and authenticated by PG 
Gunapadam Department, Govt Siddha Medical College Palayamkotttai 
Tamilnadu. 
4. Peramutti ver: 
  The raw material of pavonia odorata root was identified and authenticated by            
PG   Gunapadam Department, Govt Siddha Medical College Palayamkotttai   
Tamilnadu. 
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PURIFICATION OF RAW INGREDIENTS: 
1. Mavilingu vadaku ver: 
 It was washed with running tap water until sand, soil and dust removed. 
2. Nerunjil ver : 
It was washed with running tap water until sand, soil and dust removed. 
3. Chirupeelai ver : 
It was washed with running tap water until sand, soil and dust removed. 
4.Peramutiver: 
It was washed with running tap water until sand, soil and dust removed. 
 
PROCESS OF PREPARATION: 
 All the ingredient are purified and grind into a coarse powder by using 
machineries, this mixer powder 100 gm mix with 800 ml of water and boil it.  It 
reduced into 100 ml then filters it. 
SHELF LIFE: 
 3 hours. 
DOSAGE: 
 60 ml (1/4 to ½ ALAKKU) 
INDICATION: 
 Kalladaippu 
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Figure no 2 RAW DRUG 
 
MAVILINGU VADAKU VER                                 NERUNJIL VER 
                                                                           
 
   
CHIRUPEELAI VER                         PERUMUTTI VER 
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MAVILINGU KASAYA CHOORANAM 
 
 
 
 
 
 
 
 
 
 
 
 
MAVILINGU KASAYAM 
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                             4.2 STANDARDIZATION OF DRUG: 
 The standardization of drug is essential to exhibit the purity and quality and 
quantity of drug.  This is basically done by biochemical, physiochemical, 
phytochemical and instrumental analysis. 
 The physiochemical analysis have been done at Aravindh herbal labs (p) ltd, 
Rajapalayam, Biochemical analysis were done at Govt Siddha Medical College 
Palayamkotttai and microbiological analysis were done at inbiotics, William hospitial 
campus ms road, Nagerkovil,And the instrumental analysis was done at Indian 
Institute of Technology (IIT),Chennai-36  . 
 
Organoleptic character 
 The organoleptic characters of the sample drug were evaluated.1gm of the test 
drug was taken and the colour, texture, particle size and other morphology were 
viewed by naked eye under sunlight. Then the result is noted 
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4.2.1 PHYSICO CHEMICAL ANALYSIS 
 Physicochemical studies of the trial drug have been done according to the 
WHO guidelines. 
Determination of Ash Values: 
Total Ash: 
3g is accurately weighed and incinerated in a crucible dish at a temperature 
not exceed 450oC until free from carbon. It is then cooled and weighed. The % w/w of 
ash with reference to the air-dried powder is calculated. 
Water Soluble Ash: 
The total ash is obtained as the above method for preparation of total ash. The 
ash is boiled for 5minutes with 25ml water. The insoluble ashes is collected using 
filter paper and washed with hot water and then transferred to the silica crucible then 
ignite for 15minutes at temperature not exceeding 450oC. The silica crucible and 
residue are weighed until constant weight is attained for determination of weight of 
insoluble ash. The weight of the water soluble ash is determined by substracting the 
weight of insoluble ash from the weight of total ash. 
  
Acid insoluble Ash: 
The total ash is obtained as the above method for preparation of total ash. The 
ash is boiled for 5minutes with 25ml 10% Hcl. The insoluble ashes is collected using 
filter paper and washed with hot water and then transferred to the silica crucible then 
ignite for 15minutes at temperature not exceeding 450oC. The silica crucible and 
residue are weighed until constant weight is attained.  
Determination of Extractive Value: 
Alcohol Soluble Extractive Value: 
3g of test drug powder is weighed and macerated with 100ml of ethanol in a 
closed container for 24 hours. The resulting solution is shaken continuously for 6 
hours and allowed to stand and soak for 18 hours. The solution is filtered and 
evaporated of the filtrate in a flat bottomed shallow dish and dried at 105oC then 
cooled and weighed. 
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Water soluble Extractive value: 
3g of test drug powder is weighed and macerated with chloroform and water, 
respectively, at 80oC for 24 hrs. The resulting solution is shaken continuously for 6 
hours and allowed to stand and soak for 24 hrs then filtered. The solution from both 
chloroform and water respectively is filtered and evaporated of the filtrate in a flat 
bottomed shallow dish and dried at 105oC then cooled and weighed. 
Loss on Drying: 
The powdered drug is dried in the oven at 100- 105°C to constant weight. The 
result was noted. 
THIN LAYER CHROMATOGRAPHY 
Thin-layer chromatography(TLC) is a chromatographic technique that is 
useful for separating organic compounds. Because of the simplicity and rapidity of 
TLC, it is often used to monitor the progress of organic reactions and to check the 
purity of products.TLC is a simple, quick and inexpensive procedure that gives how 
many components are in a mixture.TLC is also used to support the identity of a 
compound in a mixture when the Rf of a compound is compared with the Rf of a 
known compound(preferably both run on the same TLC plate).Chromatography 
works on the principle that different compounds will have different solubilities and 
adsorbtion to the two phases between which they are to be partitioned. As the solvent 
rises by capillary action up through the adsorbent, differential partitioning occurs 
between the components of the mixture dissolved in the solvent stationary adsorbent 
phase. The more strongly a given component of a mixture is adsorbed on to the 
stationary phase, the less time it will spend in the mobile phase and the more slowly it 
will migrate up the plate. 
The following are some common uses of Thin-Layer 
Chromatography 
1. To determine the number of components in a mixture. 
2. To determine the identity of two substances. 
3. To monitor the progress of a reaction. 
4. To determine the effectiveness of a purification. 
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Apparatus 
 
              Flat glass plates of appropriate dimensions which allow the application at 
specified points of the necessary quantities of the solution being examined and 
appropriate reference solutions and which allow accommodation of the specified 
migration path-length. The plates are prepared as described below; alternatively, 
commercially prepared plates may be used.An aligning tray or a flat surface on which 
the plates can be aligned and rested when the coating substance is applied. 
               The adsorbent or coating substance consisting of finely divided adsorbent 
materials, normally 5 μm to 40 μm in diameter, is suitable for chromatography. It can 
be applied directly to the plate or can be bonded to the plate by means of Plaster of 
Paris (Hydrated Calcium Sulphate) or with any other suitable binders. The adsorbent 
may contain fluorescing material to help in visualising spots that absorb ultra-violet 
light.A spreader which, when moved over the glass plate, will apply a uniform layer 
of adsorbent of desired thickness over the entire surface of the plate.A storage rack to 
support the plates during drying and transportation. 
                A developing chamber that can accommodate one or more plates and can be 
properly closed and sealed. The chamber is fitted with a plate support rack that 
supports the plates, back to back, with lid of the chamber in place.Graduated micro-
pipettes capable of delivering microlitre quantities say 10 μl and less.  
                A reagent sprayer that will emit a fine spray and will not itself be attacked 
by the reagent.An ultra-violet light, suitable for observation at short (254 nm) and 
long (365 nm) ultra-violet wavelengths. 
 
 
Preparation of plates: 
Unless otherwise specified in the monograph, the plates are prepared in the 
following manner. Prepare a suspension of the coating substance in accordance with 
the instructions of the supplier and, using the spreading device designed for the 
purpose, spread a uniform layer of the suspension, 0.25 to 0.30 mm thick, on a flat 
glass plate 20 cm long. Allow the coated plates to dry in air, heat at 100º to 105º for at 
least 1 hour (except in the case of plates prepared with cellulose when heating for 10 
minutes is normally sufficient) and allow to cool, protected from moisture. Store the 
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plates protected from moisture and use within 3 days of preparation. At the time of 
use, dry the plates again, if necessary, as prescribed in the monographs 
Method 
Unless unsaturated conditions are prescribed, prepare the tank by lining the 
walls with sheets of filter paper; pour into the tank, saturating the filter paper in the 
process, sufficient of themobile phase to form a layer of solvent 5 to 10 mm deep, 
close the tank and allow to stand for 1 hour at room temperature. Remove a narrow 
strip of the coating substance, about 5 mm wide, from the vertical sides of the plate. 
Apply the solutions being examined in the form of circular spots about 2 to 6 mm in 
diameter, or in the form of bands (10 to 20 mm x 2 to 6 mm unless otherwise 
specified) on a line parallel with, and 20 mm from, one end of the plate, and not 
nearer than 20 mm to the sides; the spots should be 15 mm apart. If necessary, the 
solutions may be applied in portions, drying between applications. Mark the sides of 
the plate 15 cm, or the distance specified in the monograph, from the starting line. 
Allow the solvent to evaporate and place the plate in the tank, ensuring that it is as 
nearly vertical as possible and that the spots or bands are above the level of the mobile 
phase. Close the tank and allow to stand at room temperature, until the mobile phase 
has ascended to the marked line. Remove the plate and dry and visualise as directed in 
the monograph; where a spraying technique is prescribed it is essential that the 
reagent be evenly applied as a fine spray. 
For two-dimensional chromatography dry the plate after the first development 
and carry out the second development in a direction perpendicular to the first. 
When the method prescribed in the monograph specified ‘protected from light’ 
or ‘in subdued light’ it is intended that the entire procedure is carried out under these 
conditions. 
 
Visualisation 
The phrases ultra-violet light (254 nm) and ultra-violet light (365 nm) indicate 
that the plate should be examined under an ultra-violet light having a maximum 
output at about 254 or at about 365 nm, as the case may be. 
The term secondary spot means any spot other than the principal spot. 
Similarly, a secondary band is any band other than the principal band. 
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Rf. Value 
Measure and record the distance of each spot from the point of its application 
and calculate the Rf. value by dividing the distance travelled by the spots by the 
distance travelled by the front of the mobile phase. 
MICROBIAL LIMIT TESTS: 
DETERMINATION OF TOTAL AEROBIC MICROBIAL COUNT: 
Dissolve 10 g or dilute 10 ml of the preparation being examined, unless 
otherwise specified, in buffered sodium chloride-peptone solution Ph 7.0 or any other 
suitable medium shown to have no antimicrobial activity under the conditions of test 
and adjust the volume to 100 ml with the same medium. If necessary, adjust the pH to 
about 7. 
Membrane filtration: 
 Use membrane filters 50 mm in diameter and having anominal pore size not 
greater than 0.45 μm the effectiveness of which in retainingbacteria has been 
established for the type of preparation being examined. Sterilise andassemble the 
filtration apparatus described under tests for sterility. 
Transfer 10 ml or a quantity of each dilution containing 1 g of the preparation 
being examined to each of two membrane filters and filter immediately. If necessary, 
dilute the pretreated preparation so that a colony count of 10 to 100 may be expected. 
Wash each membrane by filtering through it three or more successive quantities, each 
of about 100 ml, of a suitable liquid such as buffered sodium chloride-peptone 
solution pH 7.0. For fatty substances add to the liquid polysorbate 20 or polysorbate 
80. Transfer one of the membrane filters, intended for the enumeration of bacteria, to 
the surface of a plate of casein soyabean digest agar and the other, intended for the 
enumeration of fungi, to the surface of a plate of Sabouraud dextrose agar with 
antibiotics. 
Incubate the plates for 5 days, unless a more reliable count is obtained in 
shorter time, at 30º to 35º in the test for bacteria and 20º to 25º in the test for fungi. 
Count the number of colonies that are formed. Calculate the number of micro-
organisms per g or per ml of the preparation being examined, if necessary counting 
bacteria and fungi separately. 
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Plate count: For bacteria: 
Using Petri dishes 9 to 10 cm in diameter, add to each dish a mixture of 1 ml 
of the pretreated preparation and about 15 ml of liquefied casein soyabean digest agar 
at not more than 45º. Alternatively, spread the pretreated preparation on the surface of 
the solidified medium in a Petri dish of the same diameter. If necessary, dilute the 
pretreated preparation as described above so that a colony count of not more than 300 
may be expected. Prepare at least two such Petri dishes using the same dilution and 
incubate at 30º to 35º for 5 days, unless a more reliable count 
is obtained in a shorter time. Count the number of colonies that are formed. Calculate 
the results using plates with the greatest number of colonies but taking 300 colonies 
per plate as the maximum consistent with good evaluation. 
For fungi: 
 Proceed as described in the test for bacteria but use Sabouraud dextrose agar 
with antibiotics in place of casein soyabean digest agar and incubate the plates at 20º 
to 25º for 5 days, unless a more reliable count is obtained in a shorter time. Calculate 
the results using plates with not more than 100 colonies. 
TESTS FOR SPECIFIED MICRO-ORGANISMS: 
Pretreatment of the sample being examined – Proceed as described under the 
test for total aerobic microbial count but using lactose broth or any other suitable 
medium shown to have no antimicrobial activity under the conditions of test in place 
of buffered sodium chloride-peptone solution pH 7.0. 
 
 
Escherichia coli: 
 Place the prescribed quantity in a sterile screw-capped container, add 50 ml of 
nutrient broth, shake, allow to stand for 1 hour (4 hours for gelatin) and shake again. 
Loosen the cap and incubate at 37º for 18 to 24 hours. 
 
Primary test: 
 Add 1.0 ml of the enrichment culture to a tube containing 5 ml of MacConkey 
broth. Incubate in a water-bath at 36º to 38º for 48 hours. If the contents of the tube 
show acid and gas carry out the secondary test. 
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Secondary test:  
 Add 0.1 ml of the contents of the tubes containing (a) 5 ml of MacConkey 
broth, and (b) 5 ml of peptone water. Incubate in a water-bath at 43.5º to 44.5º for 24 
hours and examine tube (a) for acid and gas and tube (b) for indole. To test for indole, 
add 0.5 ml of Kovac’s reagent, shake well and allow to stand for 1 minute; if a red 
colour is produced in the reagent layer indole is present. The presence of acid and gas 
and of indole in the secondary test indicates the presence of Escherichia coli. 
Carry out a control test by repeating the primary and secondary tests adding 
1.0 ml of the enrichment culture and a volume of broth containing 10 to 50 
Escherichia coli (NCTC 9002) organisms, prepared from a 24-hour culture in nutrient 
broth, to 5 ml of MacConkey broth. The test is not valid unless the results indicate 
that the control contains Escherichia coli. 
Salmonella : 
 Transfer a quantity of the pretreated preparation being examined containing 1 
g or 1 ml of the product to 100 ml of nutrient broth in a sterile screwcapped jar, shake, 
allow to stand for 4 hours and shake again. Loosen the cap and incubate at 35º to 37º 
for 24 hours. 
Primary test: 
Add 1.0 ml of the enrichment culture to each of the two tubes containing (a) 
10 ml of selenite F broth and (b) tetrathionate-bile-brilliant green broth and incubate 
at 36º to 38º for 48 hours. From each of these two cultures subculture on at least two 
of the following four agar media: bismuth sulphate agar, brilliant green agar, 
desoxycholatecitrate agar and xylose-lysine-desoxycholate agar. Incubate the plates at 
36º to 38º for 18 to 24 hours. Upon examination, if none of the colonies conforms to 
the description given in Table 2, the sample meets the requirements of the test for the 
absence of the genus Salmonella. 
If any colonies conforming to the description in Table 2 are produced, carry 
out the secondary test. 
 
Secondary test:  
 Subculture any colonies showing the characteristics given in Table 2 in triple 
sugar-iron agar by first inoculating the surface of the slope and then making a stab 
culture with the same inoculating needle, and at the same time inoculate a tube of urea 
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broth. Incubate at 36º to 38º for 18 to 24 hours. The formation of acid and gas in the 
stab culture (with or without concomitant blackening) and the absence of acidity from 
the surface growth in the triple sugar iron agar, together with the absence of a red 
colour in the urea broth, indicates the presence of salmonellae. If acid but no gas is 
produced in the sub culture, the identity of the organisms should be 
confirmed by agglutination tests.  
Carry out the control test by repeating the primary and secondary tests using 
1.0 ml of the enrichment culture and a volume of broth containing 10 to 50 
Salmonella abony (NCTC 6017) organisms, prepared from a 24-hour culture in 
nutrient broth, for the inoculation of the tubes (a) and (b). The test is not valid unless 
the results indicate that the control contains Salmonella. 
Table no: 2 – Test for Salmonella 
Medium Description of colony 
Bismuth Sulphite agar Black or green 
Brilliant green agar Small, transparent and colourless, or opaque, 
pinkish or white (frequently surrounded by a 
pink or red zone) 
Deoxycholate – Citrate agar Colourless and opaque, with or without black 
centers 
Xylose-lysine-desoxy-cholate agar  Red with or without black centres 
Pseudomonas aeruginosa : 
 Pretreat the preparation being examined as described above and inoculate 100 
ml of fluid soyabean-casein digest medium with a quantity of the solution, 
suspensionor emulsion thus obtained containing 1 g or 1 ml of the preparation being 
examined. Mix and incubate at 35º to 37º for 24 to 48 hours. Examine the medium for 
growth and if growth is present, streak a portion of the medium onthe surface of 
cetrimide agar medium, each plated on Petri dishes. Cover and incubate at 35º to 37º 
for 18 to 24 hours. If, upon examination, none of the plates contains colonies having 
the characteristics listed in Table 3 for the media used, the sample meets the 
requirement for freedom from Pseudomonas aeruginosa. If any colonies conforming 
to the description in Table 3 are produced, carry out the oxidase and pigment tests. 
Streak representative suspect colonies from the agar surface of cetrimide agar 
on the surfaces of pseudomonas agar medium for detection of fluorescein and 
pseudomonas agar medium for detection of pyocyanin contained in Petri dishes. 
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Cover and invert the inoculated media and incubate at 33º to 37º for not less than 3 
days. Examine the streaked surfaces under ultra-violet light. Examine the plates to 
determine whether colonies conforming to the description in Table 3 are present. 
If growth of suspect colonies occurs, place 2 or 3 drops of a freshly prepared 
1% w/v solution of N,N,N1,N1-tetramethyl-4-phenylenediamine dihydrochloride on 
filter paper and smear with the colony; if there is no development of a pink colour, 
changing to purple, the sample meets the requirements of the test for the absence of 
Pseudomonas aeruginosa. 
Table no: 3- Tests for Pseudomonas aeruginosa 
Medium Characteristic 
colonical 
morphology 
Fluorescence 
in UV light  
Oxidase 
test 
Gram stain 
Cetrimde 
agar 
Generally 
greenish 
Greenish Positive Negative rods 
Pseudomonas 
agar medium 
for dedection 
of 
fluorescein 
Generally 
colourless to 
yellowish 
Yellowish Positive Negative rods 
Pseudomonas 
agar medium 
for dedection 
of pyocyanin 
Generally 
greenish 
Blue  Positive Negative rods 
Staphylococcus aureus:  
Proceed as described under Pseudomonas aeruginosa. If, upon examination of 
the incubated plates, none of them contains colonies having the characteristics listed 
in Table 4 for the media used, the sample meets the requirements for the absence of 
Staphylococcus aureus.  
If growth occurs, carry out the coagulase test. Transfer representative suspect 
colonies from the agar surface of any of the media listed in Table 4 to individual 
tubes, each containing 0.5 ml of mammalian, preferably rabbit or horse, plasma with 
or without additives. Incubate in water-bath at 37º examining the tubes at 3 hours and 
subsequently at suitable intervals up to 24 hours. If no coagulation in any degree is 
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observed, the sample meets the requirements of the test for the absence of 
Staphylococcus aureus. 
Table no:4 – Tests for Staphylococcus aureus 
Selective medium Characteristic colonical morphology Gram stain 
Vogel-Johnson agar Black surrounded by yellow zones Positive cocci (in clusters) 
Mannitol-salt agar Yellow colonies with yellow zones Positive cocci (in clusters) 
Baired-Parker agar Black, shiny, surrounded by clear zones 
of 2 to 5 mm 
Positive cocci (in clusters) 
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4.2.2 BIO CHEMICAL ANALYSIS: 
Preliminary Basic and Acidic radical studies: 
Preparation of the extract: 
5gms of the test drug is weighed accurately and placed in a 250ml clean beaker.  Then 
50ml of distilled water is added and dissolved well.  Then it is boiled well for about 
10 minutes.  It is cooled and filtered in a 100ml volumetric flask and then it is made 
up to 100ml with distilled water. This preparation is used for the qualitative analysis 
of acidic/ basic radicals and biochemical constituents in it.  
QUALITATIVE ANALYSIS FOR BASIC RADICALS: 
Test for Calcium: 
 2ml of the above prepared extract is taken in a clean test tube. To this add 2ml 
of 4% Ammonium oxalate solution. Formation of white precipitate indicates the 
presence of calcium. 
Test for Iron (Ferric): 
 The extract is acidified with glacial acetic acid and potassium ferro cyanide. 
Formation of blue colour indicates the presence of ferric iron. 
Test for Iron (Ferrous): 
 The extract is treated with concentrated Nitric acid and ammonium thio-
cyanate solution. Formation of blood red colour indicates the presence of ferrous iron. 
Test for Zinc: 
 The extract is treated with potassium ferro-cyanide. Formation of white 
precipitate indicates the presence of zinc. 
QUALITATIVE ANALYSIS FOR ACIDIC RADICALS: 
Test for Sulphate: 
 2ml of extract is added to 5% barium chloride solution. Formation of white 
precipitate indicates the presence of sulphate. 
Test for Chloride: 
 The extract is treated with silver nitrate solution. Formation of white 
precipitate indicates the presence of chloride. 
Test for Phosphate: 
 The extract is treated with ammonium molybdate and concentrated nitric acid. 
Formation of yellow precipitate indicates the presence of phosphate. 
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Test for Carbonate: 
 On treating the extract with concentrated hydrochloric acid giving brisk 
effervescence indicates the presence of carbonate. 
Test for starch: 
 The extract is added with weak iodine solution. Formation of blue colour 
indicates the presence of starch. 
Test for albumin: 
 The extract is treated with Esbach`s reagent. Formation of yellow precipitate 
indicates the presence of albumin. 
Test for tannic acid: 
 The extract is treated with ferric chloride. Formation of bluish black 
precipitate indicates the presence of tannic acid. 
Test for unsaturation: 
 The extract is treated with potassium permanganate solution. The dis-
colourization of potassium permanganate indicates the presence of unsaturated 
compounds. 
Test for the reducing sugar: 
 5ml of Benedict`s qualitative solution is taken in a test tube and allowed to 
boil for 2 minutes and added 8-10 drops of the extract and again boil it for 2 minutes. 
Any colour change indicates the presence of reducing sugar. 
Test for amino acid: 
 One or two drops of the extract is placed on a filter paper and dried it well. 
After drying, 1% Ninhydrin is sprayed over the same and dried it well. Formation of 
violet colour indicates the presence of amino acid. 
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4.2.3INSTRUMENTAL ANALYSIS 
 
SEM (SCANNING ELECTRON MICROSCOPE) 
                                                 SEM INSTRUMENT 
 
                           SEM - SCANNING ELECTRON MICROSCOPE 
 
 
 
 
 
 
 
MECHANISM 
 
 In scanning electron microscope high-energy electron beam is focused through 
a probe towards the sample material. Variety of signals was produced on interaction 
with the surface of the sample. This results in the emission of electrons or photons and 
it is collected by a appropriate detector.  
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The types of signal produced by a scanning electron microscope include  
 Secondary electrons 
 back scattered electrons 
 characteristic x-rays, light 
 specimen current 
 Transmitted electrons. 
                    This gives the information about the sample and it includes external 
morphology, texture, its crystalline structure, chemical composition and it displays the 
shape of the sample. 
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FT-IR(Fourier Transform Infrared Spectroscopy): 
                                          FTIR INSTRUMENT 
 
                                 FTIR MECHANISM 
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Model   : Spectrum one: FT-IR Spectrometer 
Scan Range   :  MIR 450-4000 cm-1 
Resolution   :  1.0 cm-1 
Sample required             :  50 mg, solid or liquid. 
It is the preferred method of infrared spectroscopy. FT-IR is an important and 
more advanced technique. It is used to identify the functional group, to determine the 
quality and consistency of the sample material and can determine the amount of 
compounds present in the sample. It is an excellent tool for quantitative analysis. 
In FT-IR infrared is passed from a source through a sample. This infrared is 
absorbed by the sample according to the chemical properties and some are 
transmitted. The spectrum that appears denotes the molecular absorption and 
transmission. It forms the molecular fingerprint of the sample. Like the finger print 
there is no two unique molecular structures producing the same infrared spectrum. It 
is recorded as the wavelength and the peaks seen in the spectrum indicates the amount 
of material present.  
FT-IR is the most advanced and the major advantage is its 
 Speed 
 Sensitivity 
 Mechanical simplicity 
 Internally calibrated     
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ICP-OES (INDUCTIVELY COUPLED PLASMA OPTIC EMISSION 
SPECTROMETRY) 
 
 ICP-OES (INDUCTIVELY COUPLED PLASMA OPTIC EMISSION 
SPECTROMETRY) 
Manufacturer:Perkin Elmer 
Model   :  Optima 5300 DV ICP-OES Inductively Coupled Plasma Spectrometer 
(ICP) 
Principle : 
An aqueous sample is converted to aerosols via a nebulizer. The aerosols are 
transported to the inductively coupled plasma which is a high temperature zone 
(8,000– 10,000ºC). The analysts are heated (excited)to different (atomic and/or ionic) 
states and produce characteristic optical emissions (lights). These releases are 
separated based on their respective wavelengths and their strengths are measured 
(spectrometry). The intensities are proportional to the concentrations of analyses in 
the aqueous sample. The quantification is an external multipoint linear standardization 
by comparing the emission intensity of an unknown sample with that of a standard 
sample. Multi-element calibration standard solutions are prepared from single- and 
multi element primary standard solutions. With respect to other kinds of analysis 
where chemical speciation is relevant (such as the concentration of ferrous iron or 
ferric iron), only total essential concentration is analysed by ICP-OES. 
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Application: 
        The analysis of major and minor elements in solution samples. 
Objectives: 
 Determine elemental concentrations of different metals. 
 Learn principles and operation of the ICP-OES instrument 
 Develop and put on a method for the ICP-OES sample analysis 
 Enhance the instrumental conditions for the analysis of different elements 
 probes the outer electronic structure of atoms 
Mechanism:  
In plasma emission spectroscopy (OES), a sample solution is presented into 
the core of inductively coupled argon plasma (ICP), which generates temperature of 
approximately 8000°C. At this temperature all elements become thermally excited 
and emit light at their characteristic wavelengths. This light is collected by the 
spectrometer and passes through a diffraction grating that serves to resolve the light 
into a spectrum of its essential wavelengths. Within the spectrometer, this deflected 
light is then collected by wavelength and amplified to yield an strength of  
measurement that can be converted to an elemental concentration by comparison with 
standardizationvalues 
The Inductively Coupled Plasma Optical Emission Spectrometric (ICP-OES) 
analysis was done in Saif, IIT Madras, and Chennai-36 using Perkin Elmer Optima 
5300 DV. 
Sample preparation: 
Inductively Coupled Plasma Spectroscopy techniques are the so-called "wet" 
sampling methods whereby samples are introduced in liquid form for analysis. 
100 mg “Mavilingu kasaya chooranam”was occupied in a clean, dry test tube. 
To this, 3 ml Nitric acid was added and mixed well and allowedfor few minutes untill 
the reactions were completed. And then, 25 ml of Refined water, was added to 
prepare digested solution.  
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                   4.3 TOXICOLOGICAL STUDIES 
 
PRECLINICAL TOXICITY STUDIES OF MKC ON WISTAR 
ALBINO RATS 
4.3.1ACUTE TOXICITY STUDY IN FEMALE WISTER RATS TO 
EVALUATE TOXICITY PROFILE OF MKC 
 
OBJECTIVES 
 
The aim of this Study is to evaluate the toxicity of the test substance mavilingu kasaya 
chooranam, when administered orally to Female Wister Rats with different doses, so 
as to provide a rational base for the evaluation of the toxicological risk to man and 
indicate potential target organs. 
Guidelines followed: 
 
(a) OECD Guidelines No. 423, 
 
Study Design and Controls: 
 
1) Female Wister Rats in controlled age and body weight were selected. 
 
2) The test drug MKC was administered at 5 mg/kg, 10 mg/kg,300 mg/kg, 
1000 mg/kg, and  2000  mg/kg body weight of animal as suspension along 
with water. 
3) The results were recorded on day 0, with single oral dosing period of 14 
days.  
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EXPERIMENTAL PROCEDURE 
 
1. ANIMALS  
 
1.1. Supply 
 
        A total of 15 Female Wister Rats with an approximate age of 6 weeks and 
purchased from M/s.Venkateshwara Enterprises  Pvt. Ltd, Bangalore. On their arrival 
a sample of animals was chosen at random and weighed to ensure compliance with 
the age requested. The mean weights of Female Wister Rats were 100-150 g 
respectively.  The animals were housed in metabolic cages (55 x 32.7 x 19 cm), with 
sawdust litter, in such a way that each cage contained a maximum of 3 animals of the 
same sex. 
All animals underwent a period of 20 days of observation and acclimatization 
between the date of arrival and the start of treatment. During the course of this period, 
the animals were inspected by a veterinary surgeon to ensure that they fulfilled the 
health requirements necessary for initiation of the Study. 
1.2. Housing 
 
The Female Wister Rats were housed in metabolic cages (55 x 32.7 x 19 cm), 
placed on racks. From the week before initiation of the treatment, each cage contained 
a maximum of  3 rats of the same sex and treatment group. 
Each cage was identified by a card, color coded according to the dose level. 
This card stated the cage number, number and sex of the animals it contained, Study 
number, test substance code, administration route, dose level and Study Director's 
name, date of the arrival of the animals and initiation of treatment. 
The temperature and relative humidity were continuously monitored. Lighting 
was controlled to supply 12 hours of light (7:00 to 19:00 hours) and 12 hours of dark 
for each 24-hour period. 
The cages corresponding to each experimental group were distributed on racks 
in such a manner that external factors, such as environmental conditions, were 
balanced as far as possible. 
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2. DIET 
 
   All the rats had free access to a pelleted rat diet. The diet was analyzed by 
the   manufacturer to check its composition and to detect possible contaminants. 
 
2.1. Water 
 
The water was offered ad libitum in bottles.  
 
3. ADMINISTRATION ROUTE AND PROCEDURE 
 
          The test substance was administered orally. The Female Wister Rats belonging 
to the control group were treated with the vehicle (Water) at the same administration 
volume as the rest of the treatment groups. 
 
3.1 Numbering and Identification 
The animals were marked on body with picric acid solution prepared in water. 
The marking within the cage was as below. 
 
                                             Table no-5 Numbering and Identification 
 
 
                            
 
 
 
 
The group no., cage no., sex of the animal and animal no. were identified as 
indicated below using cage label and body marking on the animals 
     
                                                      
 
Group No Animal Marking 
1 Head 
2 Body 
3 Tail 
98 
 
 
Table no 5 Numbering and Identification 
 
 
 
 
3.2 Doses 
The doses for the study were selected based on literature search and range 
finding study. Following the period of fasting, the animals were weighed and then 
drug was administered orally as single dose using a needle fitted onto a disposable 
syringe of approximate size at the following different doses. 
                                                    Table no -6 Doses 
                   GROUP DOSE 
 
GROUP DOSE 
Group-I 5  mg/kg 
Group-II 50  mg/kg 
Group-III 300  mg/kg 
Group-IV 1000  mg/kg 
Group-V 2000  mg/kg 
 
The test item was administered as single dose. After single dose administration 
period, all animals were observed for  14days. 
 
 
 
 
Cage No Group No Animal Marking Sex 
1 I H,B,T Female 
2 II H,B,T Female 
3 III H,B,T Female 
4 IV H,B,T Female 
5 V H,B,T Female 
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Dose Preparation 
 
                                    MKC was added in distilled water and completely dissolved to 
form oral for administration. The dose was prepared of a required concentration 
before dosing by dissolving, in distilled water. It was mixed well. The preparation for 
different doses was vary in concentrations to allow a constant dosage volume. 
 
4.3 Administration 
                             
The test item was administered orally to each Female Wister rats as single dose using 
a needle fitted onto a disposable syringe of appropriate size at the following different 
doses. The concentration was adjusted according to its body weight. The volume was 
not exceeding 10 ml/kg bodyweight. Variability in test volume was minimized by 
adjusting the concentration to ensure a constant volume at all dose levels. 
 
 
4.4 Observation period 
 
All animals were observed for any abnormal clinical signs and behavioral 
changes. The appearance, change and disappearance of these clinical signs, if any, 
were recorded for approximately 1.0, 3.0 and 4.0 hours post-dose on day of dosing 
and once daily thereafter for14 days. Animals in pain or showing severe signs of 
distress were humanely killed. The cageside observation was included changes in 
skin, fur, eyes and mucous membranes, occurrence of secretions and excretions. 
Autonomic activity like lacrimation,  piloerection, pupil size and unusual respiratory 
pattern, changes in gait, posture, response to handling, presence of clonic or tonic 
movements, stereotypes like excessive grooming and repetitive circling or bizarre 
behavior like self-mutilation, walking backwards etc were observed. At the 14th day, 
sensory reactivity to stimuli of different types (e.g. auditory, visual and proprioceptive 
stimuli) was conducted. Auditory stimuli responses were measured by clicker sound 
from approximately 30 cm to the rats; visual stimuli response were measured with the 
help of shining pen light in the eye of rats and placing a blunt object near to the eye of 
rats. Response to proprioceptive stimuli was measured by placing anterior/dorsal 
surface of animals paw to the table edge. The responses of reactions for these three 
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exercises were normal in animals belonging to both the controls as well as drug 
treatment dose groups. 
 
 
 
4 Mortality and Morbidity 
 
                     All animals were observed daily once for mortality and morbidity at 
approximately 1.0, 3.0 and 4.0 hours post dose on day of dosing and twice daily 
(morning and afternoon) thereafter for 14 days 
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4.3.2 Sub-Acute Toxicity Study in Wister rats to Evaluate Toxicity 
Profile of MKC 
 
1. Objective 
The objective of this ‘Sub-Acute Toxicity Study of MKC ON Wister Rats’ 
was to assess the toxicological profile of the test item when treated as a single dose 
daily. Animals should be observed for 28 days after the drug administration. This 
study provides information on the possible health hazards likely to arise from 
exposure over a relatively limited period of time.  
 
2.Test Guideline Followed 
      OECD 407 Method - Sub-Acute Toxic Class Method (Repeated Dose 28-Day 
Oral Toxicity Study in Rodents) 
 
3. Test Item Detail 
Name: MAVILINGU KASAYA CHOORANAM 
 
4.Test System Detail 
 
The study was conducted on 5 male 5 female Wister rats for each group. 
These   animals were selected because of the recommended rodent species for oral 
studies as per followed guideline and availability of Animals 8-12 weeks old male and 
female rats were selected after physical and behavioral examination. The body weight 
range was fallen within ± 20% of the mean body weight at the time of Randomization 
and grouping. The rats were housed in standard laboratory condition in Polypropylene 
cages, provided with food and water adlibitum in the Animal at M/s. Sree 
Venkateshwara Enterprises Pvt. Ltd, Bangalore. The experimental protocol was 
approved by Institutional Animal Ethical Committee as per the guidance of 
Committee for the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA), Ministry of Environment and Forest, government of India. 
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5.  Acclimatization 
The animals were selected after veterinary examination by the veterinarian. 
All the selected animals were kept under acclimatization for a week. 
 
6.Randomization & grouping 
 
One day before the initiation of treatment (days 0- last day of acclimatization), 
the selected animals were randomly grouped into three different groups containing 
minimum 5 male and 5 female animals per group.  
 
7.Numbering and Identification 
 
The animals were marked on body with picric acid solution prepared in water. 
The marking within the cage was as below. 
 
Table no-5 Numbering and Identification 
 
 
 
     
 
Group No( C0NCENTRATION/DOSE) Animal Marking 
1. CONTROL H,B,T,HB,NM (MALE) 
H,B,T,HB,NM (FEMALE) 
2. LOW DOSE OF  MKC  2ml/kg H,B,T,HB,NM (MALE) 
H,B,T,HB,NM (FEMALE) 
3. MIDDLEDOSE OF MKC 5ml/kg H,B,T,HB,NM (MALE) 
H,B,T,HB,NM (FEMALE) 
4. HIGH DOSE OF  MKC  10ml/kg H,B,T,HB,NM (MALE) 
H,B,T,HB,NM (FEMALE) 
103 
 
The group  no., cage no., sex of the animal and animal no. were identified  as 
indicated below  using cage  label and body marking on the animals: 
 
8. Husbandry 
8.1 Housing 
The Wister rats were housed in standard polypropylene cages with stainless 
steel top grill. Paddy husk was used as bedding. The paddy husk was changed at least 
twice in a week. From the week before   initiation of the treatment, each cage 
contained a maximum of 10 rat of the differnt sex and treatment group. 
8.2 Environmental conditions 
The animals were kept in a clean environment with 12 hour light and 12 hour 
dark cycles. The air was conditioned at 22±30C and the relative humidity was 
maintained between 30-70% with 100% exhaust facility. The cages corresponding to 
each experimental group were distributed on racks in such a manner that external 
factors, such as environmental conditions, were balanced as far as possible. 
 
 
Cage No Group No 
C0NCENTRATION/DOSE 
Animal 
Marking 
Sex 
1 1. CONTROL                   
H,B,T,HB,NM                  
H,B,T,HB, NM 
 
 
Male 
Female 
2 2. LOW DOSE OF  
MKC 2ml/kg 
                  
H,B,T,HB,NM                   
H,B,T,HB, NM  
 
Male 
Female 
3 3. MIDDLEDOSE OF 
MKC 5ml/kg 
                  
H,B,T,HB,NM                   
H,B,T,HB, NM 
 
 
Male 
Female 
4 4. HIGH DOSE OF  
MKC  10ml/kg 
                  
H,B,T,HB,NM                   
H,B,T,HB ,NM  
 
Male 
Female 
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8.3 Feed & feeding schedule 
‘Sai Durga Animal Feed, Bangalore. Feed was provided adlibitum throughout 
the study period, except over night fasting (18-20 hours) prior to dose administration. 
After the substance has been administered, food was with held for a further 3-4 hours. 
 
8.4 Water 
The water was offered adlibitum in bottles. There was periodically analyzed to 
detect the presence of possible contaminants 
8.5 Doses 
The doses for the study were selected based on literature search and range 
finding study. Following the period of fasting, the animals were weighed and then 
extract was administered orally as single dose using a needle fitted on to a disposable 
syringe of approximate size at the following different doses. 
 
Table no -6 Dose level 
 
The test item was administered as single dose daily. After single dose 
administration period, all animals were observed for 28 days. 
 
 
 
TEST GROUP 
 
C0NCENTRATION/DOSE TO 
ANIMALS 
(ml/kg body-weight/day) 
 
NUMBER OFANIMALS 
Group-1 1. CONTROL 10 (5MALE and5 FEMALE) 
Group-II 2. LOW DOSE OF  MKC 2ml/kg 10(5MALE and 5 FEMALE) 
 
Group-III 3. MIDDLEDOSE OF MKC  5ml/kg 10(5MALE and 5 FEMALE) 
Group-IV 4. HIGH DOSE OF  MKC 10ml/kg 10(5MALE and 5 FEMALE) 
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Dose Preparation 
                MKC was added in distilled water and completely 
dissolved  for oral  administration. The dose was prepared of a required 
concentration before dosing by dissolving MKC in distilled water. It was 
mixed well. The preparation for different doses was vary in concentrations to 
allow a constant dosage volume. 
 
8.6 Administration 
The test item was administered orally to each   rat as single dose using a 
needle fitted on to a disposable syringe of appropriate size at the following different 
doses. The concentration was adjusted according to its body weight. The volume was 
not exceeding 10 ml/kg body weight. Variability in test volume was minimized by 
adjusting the concentration to ensure a constant volume at all dose levels. 
 
9. OBSERVATIONS  
These observations were also performed on week-ends. The 
observations included   but were not limited to changes in skin and fur, in the 
eyes and mucous membranes, in the respiratory, circulatory, central nervous 
and autonomous systems, somatomotor activity and behavior. 
 
9.1. Clinical signs of toxicity  
                       All the rats were observed at least twice daily with the purpose of 
recording any symptoms of ill- health or behavioral changes. Clinical signs of toxicity 
daily for 28 days. 
 
9.2. Food intake  
Prior to the beginning of treatment, and daily, the food intake of each 
cage was recorded for period of 28 days and the mean weekly intake per rats 
was calculated. 
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9.3. Water intake 
 
Water intake was checked by visual observation during the Study. In 
addition, the water consumption in each cage was measured daily for a 
period of 28 days. 
 
9.4 Bodyweight: 
The body weight of each rat was recorded one week before the start of treatment, and 
during the course of the treatment on the day of initial, 3rd, 7th, 10th, 14th, 17th, 20th, 
24th and 28th days (day of sacrifice). The mean weights for the different groups and 
sexes were calculated from the individual weights. 
Blood Collection   Blood was collected through retro-orbital sinus 
from all the animals of different groups on 28th day. The blood was collected 
in tubes containing Heparin/EDTA as an anticoagulant. Animals were fasted 
over night prior to the blood collection. 
LABORATORY STUDIES  
 
  During the 4th week of treatment, samples of blood were withdrawn 
from the orbital sinus of 6 rats from each group, under light ether anesthesia 
after fasting for 16 hours. The blood samples are used to evaluate 
Hematological   parameters like RBC, WBC, and PLATELETS etc….. The 
collected blood samples also centrifuged 10000 rpm in 10 minutes to 
separate the serum. The separated serum used to evaluate biochemical 
parameters like SGOT, SGPT, ALP and BILIRUBIN etc……... 
 
Hematology  
 
The following hematological parameters were analysed using Autoanalyser  
Hb  : Haemoglobin (g %)  
PCV   : Packed Cell Volume 
WBC  : White Blood Corpuscles (x103/cmm)  
RBC  : Red Blood Corpuscles (x106/cmm)  
Blood Platelet count (x103/cmm)  
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Differential WBC count:  
N  : Neutrophils (%)  
L  : Lymphocytes (%)  
M  : Monocytes (%)  
E  : Eosinophils (%)  
RDW  : Red Cell Distribution Width. 
MPV  : Mean Platelet Volume 
 
Clinical Biochemistry:  
The following clinical Bio parameters were analysed using Auto analyser  
Total serum protein (g/dl)  
ALT/SGPT  : Alanine amino transferase (U/L)  
AST/SGOT  : Aspartate amino transferase (U/L)  
ALP    : Alkaline serum phosphatase (U/L)  
CHL    : Cholesterol (mg/dL)  
HDL    : High density lipoprotein 
TG    : Triglyceride 
 
TERMINAL STUDIES  
 Sacrifice and macroscopic examination 
On completion of the 4 weeks of treatment, 18 Wister rats were 
sacrificed by ether inhalation. A full autopsy was performed on all animals 
which included examination of the external surface of the body, all orifices, 
cranial, thoracic and abdominal cavities and their contents both in situ and 
after evisceration. As the number of animals exceeded the number that could 
be sacrificed in one day, the autopsies were carried out over three 
consecutive days at the end of the treatment period.  
Organ weights: 
            After the macroscopic examination the following organs were weighed after 
separating the superficial fat: Brain, Heart, Spleen Kidneys, Testes, Liver, Lungs, 
pancreas and stomach 
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4.4PHARMACOLOGICAL STUDY 
 
4.4.1 LITHOTRIPTIC ACTIVITY 
 
EVALUATION OF LITHOTRIPTIC(ANTILITHIATIC) EFFECT 
OF MKC ON 1% ETHYLENE GLYCOL INDUCED LITHIASIS IN 
ALBINO RATS 
  
Introduction 
 
Urinary stone disease has afflicted humankind since antiquity and can persist, 
with serious medical consequences, throughout a patient’s lifetime. In addition, the 
incidence of kidney stones has been increased in western societies in the last five 
decades, in association with economic development. Most calculi in the urinary 
system arise from a common component of urine, e.g. calcium oxalate (CaOx), 
representing up to 80% of analyzed stones (51).Currently, open renal surgery for 
nephrolithiasis is unusual and used only rarely since the introduction of extracorporeal 
shockwave lithotripsy (ESWL), which has revolutionized urological practice and 
almost become the standard procedure for eliminating kidney stones. However, in 
addition to the traumatic effects of shock waves, persistent residual stone fragments 
and the possibility of infection, suggest that ESWL may cause acute renal injury, a 
decrease in renal function and an increase in stone recurrence (52,53). 
A number of vegetable drugs have been used in India and elsewhere which 
claim efficient cure of urinary stones (54). In the indigenous system of medicine, the 
mavilinga kashayam is reported to be useful in the treatment of urinary stones. 
However, so far no systematic study has been reported regarding the antiurolithiatic 
property of mavilinga kashayam. In the present study, an effort has been made to 
establish the scientific validity for the antiurolithiatic property of MKC using ethylene 
glycol induced hyperoxaluria model in rats. 
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Materials and methods 
Animal selection 
 
For acute toxicity studies, Wistar albino rat of either sex weigthing between 25 
and 30g were selected and healthy adult male Wistar albino rats weigthing between 
150 and 200g were selected for the antiurolithiatic activity. The animals were 
acclimatized to standard laboratory conditions (temperature: 25±2°C) and maintained 
on 12-h light: 12-h dark cycle. They were provided with regular rat chow (Lipton 
India Ltd., Mumbai, India) and ad libitum. The animal care and experimental 
protocols were in accordance with Institutional Animal Ethical Committee (IAEC). 
 
Acute toxicity studies 
The acute oral toxicity study (55) was carried out as per the guidelines set by 
Organization for Economic Cooperation and Development (OECD) received from 
Committee for the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA). One-tenth of the median lethal dose (LD50) was taken as an effective 
dose (56). 
 
Ethylene glycol induced urolithiasis model 
Ethylene glycol induced hyperoxaluria model (57) was used to assess the 
antilithiatic activity in albino rats. Animals were divided into six groups containing 
six animals in each. 
 
TREATMENT PROTOCOL 
The grouped animal’s received the treatment as follows 
Group I                Received normal diet and served as controls. 
Group II            Lithiatic control:  The animals were given normal diet     
                              and 1% Ethylene glycol in drinking water for 28 days.                             
Prophylactic Study: 
Group III         Received 1% ethylene glycol in drinking water and then  
treated with MKC at a dose of 100 mg/kg  
orally for 28 days  
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Group IV       Received 1% Ethylene glycol in drinking water and then 
treated with MKC at a dose of 200mg/kg           
orally for 28 days.   
           Group V         Received 1% Ethylene glycol in drinking water andthen 
treated with MKC at a dose of 300mg/kg   
orally for 28 days.   
Group VI       Received 1% Ethylene glycol in drinking water and then 
treated with cystone at a dose of 500mg/kg orally for 28 
days.   
Collection and analysis of urine 
All animals were kept in individual metabolic cages and 24 h urine samples 
were collected on 14th, and 28th day of calculi induction treatment. The volume and 
calcium content of urine were measured. Calcium in urine was estimated using kit by 
“COBAS MIRA PLUS” auto analyzer. Urine was analyzed for oxalate (58), 
magnesium (59,60), phosphate (61), uric acid (62), citrate(63) and total protein(64). 
 
 Serum analysis 
The blood was collected from the retro-orbital sinus under anesthetic condition 
and serum was separated by centrifugation at 10,000g for 10 min and analyzed for 
creatinine and uric acid. The creatinine kit (Reckon Diagnostics Pvt. Ltd., India) and 
uric acid diagnostic kit (Span Diagnostics Ltd., India) were used to estimate serum 
creatinine and uric acid levels respectively. 
 
Statistical analysis 
The results were expressed as mean ± standard error mean (SEM). The 
statistical significance was assessed using one-way analysis of variance (ANOVA) 
followed by Newmann keul’s multiple range tests and p < 0.05 was considered 
significant. 
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4.4.2 DIURETIC ACTIVITY 
 
DIURETIC ACTIVITY OF SIDDHA PREPARATION 
MAVILINUKASAYACHOORANAM 
 
Introduction  
 
Medicinal plants can be important sources of unknown chemical substances 
with potential therapeutic effects. Besides, the World Health Organization has 
estimated that over 75% of the world’s population still relies on plant-derived 
medicines, usually obtained from traditional healers, for basic health-care needs (92). 
The study of plant species with diuretic effects is still a fruitful research in search of 
new diuretics. Diuretics are the drugs that increase the rate of urine flow; clinically 
useful diuretics also increase the rate of excretion of Na+ (natriuresis) and an 
accompanying anion, usually Cl-. Most clinical applications of diuretics aim to reduce 
extracellular fluid volume (edema) by decreasing total body Nacl content. Although 
continued administration of diuretic causes a sustained net deficit in total Na+, the 
time course of natriuresis is finite because renal compensatory mechanisms brings 
Na+ excretion in line with the Na+ intake, a phenomenon known as diuretic braking. 
Diuretics alter the excretion of other cations (e.g. K+, H+, Ca2+, Mg2+), anions (e.g. 
Cl-, HCo3- and H2Po4) and uric acid. In addition diuretics may alter renal 
hemodynamics indirectly mediated by local prostaglandins synthesis(93). 
 
Despite the popular use of this species as a medicinal plant, there are no data about 
the pharmacological effect of MKC on diuretic activity. The aim of the present study 
was to evaluate the potential diuretic and natriuretic activities of MKC in 
experimental animal. 
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Material and Methods 
 
Experimental animals  
 
Healthy male albino rats weighing 180-200 g were used for the study. The 
animals were maintained in polypropylene cages of standard dimensions at a 
temperature of 37 ± 1°C and standard 12h : 12h day/night rhythm. The animals were 
fed with standard rodent pellet diet (Hindustan Lever Ltd.) and water ad libitum. Prior 
to the experiment, the animals were acclimatized to the laboratory conditions. The 
experimental protocol was approved by Institutional Animal Ethical Committee 
(IAEC) constituted under CPCSEA.  
 
Drug Treatment  
 
MKC at the dose levels of 100, 200 and 300 mg/Kg body wt., p.o. was 
administered once daily for three consecutive days. Fursemide (20 mg/Kg; p.o.) was 
used as standard for diuretic activity. Control group of animals (n=6) received normal 
saline (10 ml/Kg)  
 
Experimental design   
 
The animals were divided into 5 groups of 6 rats each as follows; Group I: 
received only 10ml/kg normal saline Group II: received Fursemide 20 mg/kg, Group 
III: received MKC 100 mg/kg body weight p.o., Group IV: received MKC 200 mg/kg 
body weight p.o.  and Group V: received MKC 300 mg/kg body weight p.o.  
 
Diuretic activity  
 
Rats were fasted overnight and treated with vehicle, Fursemide and mavilinga 
kashayam as stated above along with normal saline (10 ml/kg). The rats were placed 
in metabolic cages and the urine samples were collected for 24h, measured using a 
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standard measuring cylinder. The amount of urine (in ml) collected for 24 h was 
compared and tabulated (94).  
 
Natriuretic activity  
  
Estimation of Sodium and Potassium content of the urine samples of all 
groups of animals were done by using a laboratory model flame photometer. The ratio 
of Na+/K+ is calculated for Natriuretic activity. A value greater than 2.0 indicates a 
favorable Natriuretic effect. Ratio greater than 10.0 indicates a potassium sparing 
effect(95).  
 
Statistical analysis  
 
The results were expressed as mean ± S.E.M. Statistical comparisons were made by 
means of newmann keuls multiple range tests. p values smaller than 0.05 was 
considered as significant. 
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4.4.3 ANTISPASMODIC ACTIVITY 
 
IN-VITRO ANTISPASMODIC ACTIVITY OF MKC ON EXCISED 
RAT ILEUM 
 
ISOLATION OF RAT ILEUM:-  
 
 Rats were anesthetized and sacrificed by cervical displacement followed by 
exsanguinations. The ileum was dissected out, immersed in Tyrode’ssolutionand 
cleaned off the mesentery. Respective segments of 2-3cm long were mounted in a 
25ml tissue organ bath, filled with a mixture of 95% O2 and 5% CO2 and maintained 
at 37 o C. The composition of Tyrode’s solution (in mM for l lit) was 9 mg KCl, 0.1 
mg NaCl, 0.1mg NaHCO3, 0.42mg NaH2PO4, 0.6 mg Glucose and pH value was 7.4.  
 
ANTI-SPASMODIC ACTIVITY ASSAY PROCEDURE:-  
 
1. Firstly concentration dependent responses of acetylcholine were recorded 
(with dose of 0.1ml, 0.2ml, 0.4ml, 0.8ml, 1.6ml, 3.2ml) using Sherrington’s 
recording drum with a frontal writing lever. Contact time of 60 sec, and base 
line of 30sec time cycle were opted for proper recording of the responses in 
presence of plane Tyrode’s solution as stock-I solution.  
 
2.  Then same concentration dependent responses of acetylcholine (Ach) using 
same procedure for a mixture of Tyrode’s solution+ Lantana camara extract 
(with a concentration of 1mg/ml) as a stock-II solution were recorded.  
 
3.  Lastly the same concentration dependent responses of Ach for a mixture of 
Tyrode’s solution+ Atropine (as a standard antispasmodic agent) as a stock-III 
solution were recorded. 
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5. MICROBIOLOGICAL ANALYSIS 
ANTI - MICROBIAL STUDIES  
 
Aim 
       To study the Anti-microbial action of MAVILINGU KASAYAM  
Components of Muller Hinton agar medium 
         Beef extract - 300gms/lit 
         Agar - 17 gms/lit 
         Starch - 1.5 gms/lit 
         Casein Hydrolysate - 17.5 gms/lit 
         Distilled water - 1000 ml 
         PH - 7.  
 
    PRINCIPLE : 
 
                                    The antimicrobials present in the plant extract are allowed to 
diffuse out into the medium and interact in a plate freshly seeded with the test 
organisms. The resulting zones of inhibition will be uniformly circular as there will be 
a confluent lawn of growth. The diameter of zone of inhibition can be measured in 
millimeters. 
 
PROCEDURE (Murray et al., 1995) 
 
                               Petriplates containing 20ml Muller Hinton medium were seeded 
with 24hr culture of bacterial strains. Wells were cut and 20 µl of the plant extracts 
(aqueous) were added. The plates were then incubated at 37°C for 24 hours. The 
antibacterial activity was assayed by measuring the diameter of the inhibition zone 
formed around the well (NCCLS, 1993). Streptomycin was used as a positive control. 
Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken HR Manual of Clinical 
Microbiology, 6th Ed. ASM Press, Washington DC, 1995; 15-18. 
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Methodology: 
           Muller Hinton Agar plates are prepared and Pseudomonas, Staphylococcus, 
Enterococcus, Escherichia coli, Streptococcus,klebsiella is inoculated separately. 
The prepared disc of maviligukasayam are placed over the incubated plate using 
sterile forceps and incubated for 24 hours at 37 degree celcius. The plates after 24 
hours incubation are observed for the zone of inhib 
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6. RESULTS AND DISCUSSION 
 
The Siddha herbal drug mavilingu kasayam had been subjected to various 
studies to establish the works of Siddhars to be true. Literary collections, 
physicochemical and Elemental analysis, toxicological study, pharmacological study 
and clinical study are done to prove the activity of mavilingu kasayam in lithotriptic, 
diuretic, anti-spasmodic activity. 
 
 Standardisation of the test drug 
Standardisation of the drug is more essential to derive the efficacy and potency of 
the drug, which was analysed by the various methods.  The results of physicochemical 
and biochemical analysis have been done and tabulated. Pharmacological activity and 
toxicological results of the drug were derived. The results reveal the effectiveness of 
the trial drug mavilingu kasayam has been proved by the following scientific 
parameters. 
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PHYSIOCHEMICAL ANALYSIS 
 
The following characters have been noted in MKC                                                                     
  
Organoleptic characters 
                                                        Table no-7 
Colour in day light Greenish yellow 
Smell Pleasant odour  
Taste Bitter, L.Pungent 
Appearance  powder 
Touch Nice 
 
 
 
 
 
Table no-8 Physicochemical properties 
 
Table 
S.NO 
 
Parameter 
 
Result 
1 Loss on drying  5.2% 
2 Ash content 8.1% 
3 Acid insoluble ash 1.3% 
4 Water sol.matter 21.5% 
5 Alcohol sol.matter 18.9% 
6 PH 6 
7 Nice  coarse powder 
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Interpretation: 
 
Total Ash: Total ash value of plant material indicated the amount of minerals and 
earthy materials present in the plant material. The total inorganic content (ammonium, 
potassium, calcium, chloride, iron, etc.,) present in the drug is measured through the 
Total ash value. The total ash value of the drug was determined as 8.1%. 
Acid insoluble ash: The acid insoluble ash value of the drug denotes the amount 
of siliceous matter present in the plant. The quality of the drug is better if the acid 
insoluble value is low. It is 1.3% for the drug. 
Water soluble ash: Water-soluble ash is the part of the total ash content, which is 
soluble in water. It is 21.5% for the drug 
Alcohol soluble ash: Alcohol-soluble ash is the part of the total ash content, 
which is soluble in alcohol. It is 18.9% for the drug 
 These are indicating the approximate measure of chemical constituents of 
crude drug. 
 The percentage of soluble matters present in the drug is determined by the 
values of water extractive and ethanol extractive.  
 Water-soluble extractive value plays an important role in evaluation of crude 
drugs 
 The alcohol-soluble extractive value was also indicative for the same purpose 
as the water-soluble extractive value 
Loss on drying: 
 The total of volatile content and moisture present in the drug was established 
in loss on drying.  
 Moisture content of the drug reveals the stability and its shelf-life.  
 High moisture content can adversely affect the active ingredient of the drug.  
 Thus low moisture content could get maximum stability and better shelf life. 
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MICROBIAL LIMIT TESTS: 
 
Table No: 9 Results for Microbial limit test : 
 
S.No Microbes Colony 
measurements 
1.  Total viable aerobic count 1.6 x104 col/g 
2.  Total Enterobacteriaceae Nil 
3. Total fungal count 3.5 x102 col/g 
 Test for specific pathogen  
1. Salmonella sp Nil 
2. Staphylococcus aureas Nil 
3. E.coli Nil 
4. Pseudomonas aeruginosa Nil 
 
 
Interpretation: 
Microbial Limit Tests 
  
The total bacterial count and the total fungal count of the drug were found to be 
within the WHO prescribed limits which indicate that the drug is free from microbial 
condamination. The other pathogens like Escherichia coli, Salmonella sps, 
Pseudomonas aeruginosa and Staphylococcus aureus were found to be completely 
absent in the drug  
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THIN LAYER CROMATOGRAPY (TLC): 
                                                         Figure no:3 
 
 
Interpretation: 
            Spots of green, blue colours were detected on the chromatoplates under 
UVlight.The Rf value of spots in the sample was approximately 
green(0.71,0.67,0.57,0.50,0.36,0.27,0.13) blue(0.71,0.67,0.57,0.50,0.36).it indicates 
the presence of active compound in the sample which is responsible for the 
therapeutic effect. 
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BIO-CHEMICAL ANALYSIS OF “MAVILINGU KASAYAM” 
 
Table No: 10 Preliminary tests for basic and acidic radical: 
 
S.NO EXPERIMENT 
 
INFERENCE 
1. TEST FOR CALCIUM:          Absent 
2. TEST FOR SULPHATE: Present 
3. TEST FOR CHLORIDE: Absent 
4. TEST FOR CARBONATE: 
 
          Absent 
5. TEST FOR STARCH: 
 
Absent 
6. TEST FOR IRON FERRIC: Absent 
7. TEST FOR IRON FERROUS: 
 
Present 
8. TEST FOR PHOSPHATE: 
 
Present 
9. TEST FOR ALBUMIN: 
 
Absent 
10. TEST FOR TANNIC ACID: 
 
Absent 
11.  TEST FOR UNSATURATION: 
 
Present 
12. TEST FOR THE REDUCING SUGAR: Absent 
13.  TEST FOR AMINO ACID:      
 
Absent 
14. TEST FOR ZINC: Absent 
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Interpretation: 
 
Sulphate: 
 Sulphate may prevent the occurrence of any infection 
 Sulphate is potent anti oxidant activity in human body[46] 
 The main function of sulfate is to stabilize protein structure. 
 Sulphate ion is used as counter ion for some cationic drug 
 Sulphate has anti bacterial activity and it is one of the macronutrient of 
cells. It inhibits growth of yeasts and moulds in low pH and inhibits growth 
of enterobacteriae and other gram- negative bacteria in high pH 
 
Iron: 
 Iron improves the haematological level in the body and also it is essential for 
growth, reproduction, healing and immune function. 
 In this the iron is present in ferrous form, which is soluble and readily 
absorbed in the intestinal lumen. 
 The  heme  containing enzymes such as catalase and peroxidase protect cell 
against potentially damaging highly reactive species 
 
 Iron is needed for transporting oxygen and carbon dioxide. It also has other 
important roles in the body. 
 
PHOSPHATE: 
 The recommended dietary allowance of phosphate is based on the intake of 
calcium, the of Ca:P of 1:1 is recommended 
 Phosphate filters out waste in your kidneys. 
 Phosphate growth, maintains, and repair tissue and cells. 
 Phosphate balance and use vitamins such as vitamins B and D, as well as other 
minerals like iodine, magnesium, and zinc. 
 It assists in muscle contraction. 
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                                  INSTRUMENTAL ANALYSIS 
 
SEM RESULT:Figure no:4 
 
   
    
SEM picture 30,000 magnification 
 
  
 
SEM picture 60,000 magnification 
125 
 
 
 
Interpretation for SEM 
 
 The morphology of the Mavilingu kasayam sample can be determined by 
Environmental SEM (FEI Quanta). A representative portion of each sample must be 
sprinkled onto a double side carbon tape and mounted on aluminium stubs, in order to 
get a higher quality secondary electron image for SEM examination. We have 
observed from SEM photographs that particles are spherical in shapes and sizes are in 
the range from 0.5 micron to 1 micron. Although the particle sizes of different batches 
showed similarity, it seems that these particles are aggregates of much smaller 
particles. When dispersed in an aqueous medium, these preparations form a 
negatively charged hydrophobic particle suspension. This hydrophobicity gives these 
particles a tendency to aggregate together to form larger particles. Mavilingukasayam 
exhibited larger sizes and agglomeration of the particles. Therefore, the comparatively 
larger size may be due to the agglomeration of the particles by repeated cycles of 
calcinations involved in preparation. 
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FTIR RESULTS OF MKC: 
Figure No: 5 FTIR Result Graph 
 
 
 
 
Table no - 11  Table showing represented functional groups 
 
 
Absorption peak cm-1 
 
                Stretch 
 
 
Functional group  
         3389 O-H stretch,H-Bonded Alcohols,phenols 
 
         2921 C-H stretch Alkenes 
 
         2120 C(triple bond)C- stretch Alkynes 
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833
775
615
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         1736 C=O Stretch Esters,saturated 
aliphatic 
 
         1640 -C=C- Alkenes 
 
         1512 N-O asymmetric stretch Nitro compound 
 
         1427 C-C stretch(in ring) Aromatics 
 
         1383 C-H bend Alkenes  
 
         1319 C-N stretch Aliphatic, amines 
 
         1241 C- N stretch Aliphatic, amines 
 
         1048 C-N stretch Aliphatic, amines  
         833 
 
C-Cl stretch Alkyl halides 
          775 C-H “oop” Aromatics 
 
           615 C-Br stretch Alkyl halides 
 
Interpretation: 
 
In FTIR the wave numbers between 4000cm-1-400cm-1. 4000 cm-1-1500 cm-1 is known 
as functional group area.1500 cm-1-600cm-1 is known as finger print area. The 
identity of FTIR of two compounds is much more characteristic than the comparision 
of their many physical properity. The corresponding absorption frequency by FTIR 
shows the presence of alcohols, phenols, alkenes, amines, aliphatic amines, alkyl 
halides, nitrocompound, aromatics esters, saturatedaliphatic, alkynes. 
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Amines groups: 
 Amines groups act as neurotransmitters. 
 It is involved in protein synthesis. 
 This group of substances has analgesic activity. 
Alcoholic groups: 
 Alcoholic group of substances act as antimicrobial and antiseptic agents. 
Phenolic groups: 
 Phenolic group act as neurotransmitters. 
 This group of substance has antimicrobial, antiseptic and antioxidant 
activities. 
Alkanes groups: 
 Alkanes have little biological activity. 
 It is predominate in plants. They protect against bacteria and fungi.[45,46,48] 
Alkyl Halides: 
 These are group of compounds derived from alkanes containing one or more 
halogens.Some are used as anesthetics and antiseptic agents. Some of them are 
used in medicine for the elimination of hook worms  
AROMATICS: 
 Aromatics are good pain relievers. Auto-immune activities. 
Ester: 
 Esters are organic compound formed when an acid combine with an alcohol 
and release water. Ester of Sitostanol decrease in cholesterol absorption  
Alkyne: 
 Alkyne conjugated probes which plays an important role in inflammation  
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ICP-OES (Inductively Coupled Plasma Optical Emission 
Spectroscopy): 
 
The drug MKC sample was analysed by the Inductively Coupled Plasma 
Optical Emission Spectroscopy (ICP-OES) to detect the trace elements and other 
elements quantitatively. The result of ICP-OES is given on the Table No: 12.  
 
Sample ID Elements Symbol Wavelength(nm) Concentration (A)P 
1. Al 1396.152 BDL 
2. As 188.979 BDL 
3. Cd 228.802 BDL 
4. Ni 231.604 BDL 
5. Pb 220.353 BDL 
6. Cu 327.393 BDL 
7. Hg 253.652 BDL 
8. Ca 315.807 72.180mg/l 
9. K 766.491 83.821 mg/l 
10. Fe 238.204 22.376mg/l 
11. Mg 285.213 02.104 mg/l 
12. Na 589.592 74.320 mg/l 
13. P 213.617 106.341mg/l 
14. Zn 206.200 02.228mg/l 
15. S 180.731 01.314 mg/l 
 
 
BDL:Below Detectable Limit ( Normal – 1 ppm) 
1% = 10000ppm, 
1ppm = 1/1000000 or 1ppm = 0.0001% 
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The toxic metals and the permissible limits 
Heavy metals  WHO & FDA limits  
Arsenic (As)  10ppm 
Mercury (Hg)  1ppm 
Lead (Pb)  10ppm 
Cadmium (Cd) 0.3ppm 
 
 
Plants are the rich source of elements. These elements have vital function. 
They were significant role against a variety of diseases. Hence they were used for 
several health problems. 
The MKC showed presence of Ca,Na, K, Mg, Zn,P,S,Fe. In mavilingu 
kasayam, the heavy metals like As, Hg, Cd, Pb,Cu and trace element like Ni,Al were 
below detectable level. The result indicate that the formulation is extremely safe as it 
contains heavy metals within specified limits.  
Interpretation: 
 
 Sodium :sodium is an impartant component in the humen body.The human 
diet has requirement of 1.5grams of sodium intake everyday.sodium regulate 
the blood pressure and regulate blood volume.it help to transmit impulses for 
nerve and muscle contrction. It regulat the acid balance.Too much of sodium 
can be harmful to kidney disease.because kidney cannot eliminate excees 
sodium.so sodium restriction is recommended if blood presser is high and ckd 
condition.                                                                             
 Potassium: In the presence of Sodium and Potassium regulate the acid-base 
balance of the body fluids.They regulate the water balance of the body 
fluids.They help to preserve the neuromuscular irritability by maintaining a 
state of equilibrium on account of their relative proportion in the Extra 
cellular fluid and Intra cellular fluid. Potassium is an electrolyte critical in 
maintaining proper acid-alkaline balance. Potassium is highly present inintra 
cellular fluid( ICF), while its partner, sodium, is highly present in extra 
cellular fluid( ECF).It is their perfect ratio that maintains fluid and electrolyte 
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balance. Potassium dilates the arteries and relaxes the smooth muscles and 
increases the blood flow (F.J. Haddy, 2012). 
 
 Calcium: Calcium is an important component of cellmembrane. It controls i 
permeability and electrical properties of the cellmembrane. Calcium necessary 
for the maintenance and regulation of acid –base balance and water balance in 
the body.   Calcium from food can help prevent kidneystone formation & help 
maintain bone density. Decreasing calcium intake; this will increases oxaluria  
 Magnesium:Magnesium inhibits the formation of calcium-oxalate crystals 
in the urine. It  also inhibit  the stone formation by inhibition of growth of 
crystals as well as aggregation. Inhibition of crystal attachment of calcium 
oxalate appears to require supra-physiologic concentrations.Magnesium 
reduces  the formation of stones by reducing the calcium oxalate in the blood 
that makes up the stones. 
 
 Zinc: Mg, Zn which are considered to be stone inhibitors and anti microbial 
activity against E.coli which in the commonest urinary tract infection among 
patients with urolithiasis57. Zinc is a micro nutrient and is required for wound 
healing. 
 
 Phosphorus:  Phosphorus is an important constituents of phosphate buffers 
in the blood and urine.It is required for the formation of certain 
physiologically important phosphorus containing compounds like 
phospholipids, coenzymes and enzymes of intermediary metabolism 
 
 Iron:In this the iron is present in ferrous form, which is soluble and readily 
absorbed in the intestinal lumen.The  heme  containing enzymes such as 
catalase and peroxidase protect cell against potentially damaging highly 
reactive species. Iron is needed for transporting oxygen and carbon dioxide. It 
also has other important roles in the body.Iron is essential for oxygen 
transport, energy production, and cellular growth and proliferation.Iron 
deficiency may be determined by measurement of iron levels within the body, 
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mainly serum ferritin levels, which may also help distinguish between iron 
deficiency                                                                                                                                    
 Most of the iron in the body is found in the hemoglobin of red blood cells and 
in the myoglobin of muscle cells and anemia associated with chronic disease, 
such as chronic kidney disease (CKD) 
 
 Sulphate: Sulphate may prevent the occurrence of any infection. Sulphate is 
potent anti oxidant activity in human body . The main function of sulfate is to 
stabilize protein structure. Sulphate ion is used as counter ion for some 
cationic drug.  Sulphate has anti bacterial activity and it is one of the 
macronutrient of cells. It inhibits growth of yeasts and moulds in low pH and 
inhibits growth of enterobacteriae and other gram- negative bacteria in high Ph 
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TOXICITY STUDIES 
EVALUATION OF ACUTE TOXICITY OF MKC 
 Effect of Acute Toxicity (14 Days) of MKC 
 RESULT    Table no –13 Physical and behavioral examinations. 
Group no. Dose(mg/kg Observation sign No. of animal affected. 
Group-I 5mg/kg Normal 0 of 3 
Group- II 50mg/kg Normal 0 of 3 
Group-III 300mg/kg Normal 0 of 3 
Group-IV 1000mg/kg Normal 0 of 3 
Group-V 2000mg/kg Normal 0 of 3 
 
Table no-14 Home cage activity 
 
Functional 
and 
Behavioural 
observation 
Observation 5mg/kg 
Group 
(G-I) 
50mg/kg 
(G-II) 
300mg/kg 
(G-III) 
 
1000mg/kg 
(G-IV) 
2000mg/kg 
(G-V) 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
Female n=3 
Body position Normal 3 3 3 3 3 
Respiration Normal 3 3 3 3 3 
Clonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Tonic 
involuntary 
Movement 
Normal 3 3 3 3 3 
Palpebral 
closure 
Normal 3 3 3 3 3 
Approach 
response 
Normal 3 3 3 3 3 
Touch 
response 
Normal 3 3 3 3 3 
Pinna reflex Normal 3 3 3 3 3 
Tail pinch 
response 
Normal 3 3 3 3 3 
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Table no-15  Hand held observation 
Functional and 
Behavioral 
observation 
Observati
on 
Contr
ol 
5 
mg/ 
kg  
(G-
I) 
50 
mg/
kg 
(G-
II) 
300
mg/
kg 
(G-
III) 
1000mg
/kg 
(G-IV) 
2000mg/
kg 
(G-V) 
Femal
e n=3 
Fem
ale 
n=3 
Fem
ale 
n=3 
Fem
ale 
n=3 
Female 
n=3 
Female 
n=3 
Reactivity Normal 3 3 3 3 3 3 
Handling Normal 3 3 3 3 3 3 
Palpebral closure Normal 3 3 3 3 3 3 
Lacrimation Normal 3 3 3 3 3 3 
Salivation Normal 3 3 3 3 3 3 
Piloerection Normal 3 3 3 3 3 3 
Pupillary reflex Normal 3 3 3 3 3 3 
Abdominal tone Normal 3 3 3 3 3 3 
Limb tone Normal 3 3 3 3 3 3 
 
 
Table no-16 Mortality 
Group no Dose no(mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 2000(mg/kg) 0 of 3 
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RESULT: 
 
 From acute toxicity study it was observed that the administration of MKC at a 
dose of 2000 mg/kg to the rats do not produce drug-related toxicity and mortality. So 
No-Observed-Adverse-Effect- Level (NOAEL) of MKC is 2000 mg/kg. 
 
INTERPERTATION: 
 
MKC was administered single time at the dose of 5mg/kg, 50mg/kg , 300mg/kg, 
1000mg/kg and 2000mg/kg to rats and observed for consecutive 14 days after 
administration. Doses were selected based on the pilot study and literature review. All 
animals were observed daily once for any abnormal clinical signs. Weekly body 
weight and food consumption were recorded. No mortality was observed during the 
entire period of the study. Data obtained in this study indicated no significance 
physical and behavioural signs of any toxicity due to administration of MKC at the 
doses of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand held 
activity were observed. Home cage activities like Body position, Respiration, Clonic 
involuntary movement, Tonic involuntary movement, Palpebral closure, Approach 
response, Touch response, Pinna reflex, Sound responses, Tail pinch response were 
observed. Handheld activities like Reactivity, Handling, Palpebral closure, 
Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, Limb tone 
were observed. Functional and behavioral examination was normal in all treated 
groups.Food consumption of all treated animals was found normal as compared to 
normalgroup. 
Body weight at weekly interval was measured to find out the effect of MKC 
on the growth rate. Body weight change in drug treated animals was found normal. 
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Sub-Acute Toxicity Study in Wister rats to Evaluate Toxicity Profile 
of MKC 
Results and Interpretation of 28-day repeated dose oral toxicity study 
in rats                                Table no-17 
EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MKC ON BODY WEIGHT 
 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated by one 
way ANOVA  followed by dunnett’s. ns- not significant **P< 0.05 calculated by 
comparing treated group with control group 
 
 
 
 
 
 
 
 
GROUP 
 
 
CONTROL 
 
       MKC            
LOW DOSE 
 
     MKC      
MIDDLE DOSE 
 
     MKC            
HIGH DOSE 
 
1st day 
 116.5±1.25831 115.833±2.76184 114.667±3.22146 108±2.17562 
 
7th day 
 126.5±2.17179 121.667±2.69155 121.667±2.24598 118.833±0.980363 
 
14th day 
 132.833±1.44722 130.667±3.25235 130±2.0166 129±1.89737 
 
21st day 
 139.167±1.35195 140.5±1.17615 136.333±2.1551 140.333±1.2561 
 
28th day 
 143.833±1.74005 144±1.98326 145.333±1.72562 141.833±1.01379 
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 EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MKC ON FOOD 
INTAKE IN gms Table no -18 
 
 
 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated 
by one way ANOVA  followed by dunnett’s. ns- not significant **P< 0.05 calculated 
by comparing treated group with control group 
 
 
 
 
 
 
 
 
 
GROUP CONTROL 
 
MKC          LOW 
DOSE 
      
MKC    
MIDDLE DOSE  
MKC HIGH DOSE 
 
1st day 
 39.3333±2.09231 37.8333±3.8159 36.3333±2.76486 38±4.93288 
 
7th day 
 47.6667±3.13759 47.3333±2.77689 40.8333±1.85143 42.1667±2.57445 
 
14th day 
 47.5±2.86065 48.6667±2.61619 54.1667±6.62026 50.1667±4.09403 
 
21st day 
 53±3.06594 54.1667±1.90467 59.6667±3.3731 55.3333±4.55827 
 
28th day 
 54.1667±3.45848 49.1667±2.68845 51.1667±3.40016 51.6667±2.71621 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MKC 
WATERINTAKE IN gms Table no19 
 
 
 
 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated by one 
way ANOVA  followed by dunnett’s. ns- not significant **P< 0.05 calculated by 
comparing treated group with control group 
 
 
 
 
 
 
 
                                                                 
                                                    
 
 
GROUP 
 
 
CONTROL 
 
       MKC            
LOW DOSE 
 
     MKC      
MIDDLE DOSE 
 
     MKC            
HIGH DOSE 
 
1st day 
 33.3333±6.08094 39.8333±5.51009 33.5±2.66771 85.8333±5.0492 
 
7th day 
 43.5±8.65544 56±6.3456 42.5±6.37574 54.8333±6.36352 
 
14th day 
 65.8333±4.98275 87.6667±2.69155 81.6667±4.86256 65.8333±4.98275 
 
21st day 
 91.8333±3.43915 94±5.07937 81.3333±1.85592 88.6667±3.10555 
 
28th day 
 96.3333±2.77689 86.6667±1.68655 91±3.25576 85±5.09902 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MKC ON BODY WEIGHT 
IN gms      Figure no- 6 
 
 
                                                              
EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MKC ON FOOD INTAKE 
IN gms    Figure no:7 
 
 
 
 
 
 
EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MKC WATERINTAKE IN 
GMS    Figure no:8 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MKC ON 
ORGAN WEIGHT IN gms Table no 20 
 
 
 
 
 
 
 
 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated 
by one way ANOVA  followed by dunnett’s. ns- not significant **P< 0.05 calculated 
by comparing treated group with control group 
 
 
 
 
 
 
 
 
GROUP 
 
 
CONTROL 
 
       MKC            
LOW DOSE 
 
     MKC      
MIDDLE 
DOSE 
 
     MKC            
HIGH DOSE 
 
BRAIN 
 1.379±0.198698 
1.37633±0.1524
71 
1.43933±0.1694
12 
1.51267±0.095
919 
 
HEART 
 
0.590667±0.018
9854 
0.540667±0.036
7892 
0.536667±0.034
5704 
0.509333±0.12
0257 
 
LIVER 
 
6.44267±0.1931
68 
6.59433±0.1332
25 
5.77067±0.6520
78 
5.211±0.53389
6 
 
LUNGS 
 0.979±0.171966 
1.47567±0.0764
991 
1.36167±0.0974
241 
2.26967±0.108
201 
 
TESTIS 
 
2.15867±0.1426
25 2.281±0.146848 
3.02667±0.0977
707 
2.256±0.06502
31 
 
UTRES 
 
0.722±0.026274
2 
0.736±0.045489
9 
0.675333±0.069
2082 
0.546±0.14905
5 
 
KIDN
EY 
 
 
L 
 
 
 
0.576±0.0394 
 
0.6287±0.07753 
0.5847±0.09359 
0.4657±0.0815
8 
R 
 
0.5477±0.05045 0.5203±0.08391 
0.5553±0.0452 0.523±0.1544 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MKC ON ORGAN 
WEIGHT IN gms Figure no:9 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MKC ON 
HAEMATOLOGICAL PARAMETERS 
 
Table no-21 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated by one 
way ANOVA  followed by dunnett’s. ns- not significant **P< 0.05 calculated by 
comparing treated group with control group 
  
 
GROUP 
 
 
CONTROL 
 
       MKC            
LOW DOSE 
 
     MKC      
MIDDLE 
DOSE 
 
     MKC            
HIGH DOSE 
 
RBC 
(X10^6µL) 
 
4.935±0.5694
08 
6.1775±0.3280
85 
6.055±0.46053
4 
5.875±0.47147
8 
 
WBC(X10^3µL
) 
 
13.075±1.409
71 
12.275±0.3772
16 
12.45±0.87034
5 
11.325±0.7330
02 
 
HB (g/dl) 
 
 9.5±0.514782 12.605±1.5332 
11.525±0.6823
67 
12.75±0.79004
2 
 
POLYMORPH
S % 
 
7.75±0.75 
 
10±1.08 
 
9±1.08 
 
8.25±0.8539 
 
 
LMPHOCYTE
S% 
 
92.75±1.6520
2 85.75±2.59406 86.75±3.37577 89.5±1.70783 
 
MONOCYTES 
% 
 
8.25±0.85391
3 7±0.408248 7.25±0.75 5.75±0.478714 
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 EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MKC ON        
HAEMATOLOGICAL PARAMETERS Figure no:10 
 
 
RBC
CO
NT
RO
L
M 
K 
.L.
D
M 
K.
M.
D
M 
K.
H.
D
0
2
4
6
8
X1
0^
6 µ
L
                     
WBC
CO
NT
RO
L
M 
K 
.L.
D
M 
K.
M.
D
M 
K.H
.D
0
5
10
15
20
X1
0^
3µ
L
 
 
HB
CO
NT
RO
L
M 
K .
L.D
M 
K.M
.D
M 
K.
H.
D
0
5
10
15
g/
dl
                       
POLYMORPHS
CO
NT
RO
L
M 
K 
.L.
D
M 
K.
M.
D
M 
K.
H.
D
0
5
10
15
%
 
 
 
 
LYMPHOCYTES
CO
NT
RO
L
M 
K 
.L.
D
M 
K.
M.
D
M 
K.
H.
D
0
20
40
60
80
100
%
                  
MONOCYTES
CO
NT
RO
L
M 
K 
.L.
D
M 
K.
M.
D
M 
K.
H.D
0
2
4
6
8
10
%
 
 
 
 
 
 
 
 
 
 
 
144 
 
 
 
EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MKC ON 
BIOCHEMICAL PARAMETERS Table no-22 
 
 
 
Table no-23 TOTAL BILURUBIN 
 
 
 
 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated by one 
way ANOVA  followed by dunnett’s. ns- not significant **P< 0.05 calculated by 
comparing treated group with control group 
 
 
 
  
 
GROUP 
 
 
CONTROL 
 
       MKC            
LOW DOSE 
 
     MKC      
MIDDLE 
DOSE 
 
     MKC            
HIGH DOSE 
SGOT 
(U/L) 
 
92.6±10.416 
 
107.48±15.8746 
 
88.8033±5.3248
5 
 
75.0333±2.7088
3 
 
 
SGPT(U/L
) 
 
36.44±4.64251 
 
93.6667±19.742
5 
 
53.5±4.05956 
 
37.0333±3.9641
4 
 
 
ALP (U/L) 
 
129.667±2.1858
1 
 
137±6.08276 
 
122.333±2.9627
3 
 
151.4±27.1048 
 
 
GROUP 
 
 
CONTROL 
 
       MKC            
LOW DOSE 
 
     MKC      
MIDDLE 
DOSE 
 
     MKC            
HIGH DOSE 
 
TOTAL 
BILURUBIN 
(g/ml) 
 
1.323±0.0409 
 
1.44±0.09165 
 
1.777±0.193 
 
1.51667±0.095 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MKC ON BIOCHEMICAL  
 
PARAMETERS Figure no:11 
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Table no-24 UREA,URIC ACID,CREATININE  
 
  Values are expressed as the mean ± S.D. Statistical significance (p) calculated by 
one way ANOVA  followed by dunnett’s. ns- not significant **P< 0.05 calculated by 
comparing treated group with control group 
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GROUP 
 
 
CONTROL 
 
       MKC            
LOW DOSE 
 
     MKC      
MIDDLE 
DOSE 
 
     MKC            
HIGH DOSE 
 
UREA 
(mg/dl) 
 
14.5333±1.647
56 
 
20.2333±1.217
01 
 
17.9333±4.1167
7 
 
18.8±1.61658 
 
 
URIC ACID 
(mg/dl) 
 
3.2±0.305505 
 
2.35±1.11168 
 
2.16667±0.1763
83 
 
2.43333±0.3480
1 
 
 
CREATINI
NE  
(mg/dl) 
 
0.34±0.043589 
 
0.4066±0.0233 
 
0.5033±0.04333 
 
0.603333±0.099
55 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MKC ON 
ELECTROLYTES Table no 25 
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Figure no:12 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated by one 
way ANOVA  followed by dunnett’s. ns- not significant **P< 0.05 calculated by 
comparing treated group with control group. 
 
 
 
 
GROUP 
 
 
CONTROL 
 
       MKC            
LOW DOSE 
 
     MKC      
MIDDLE 
DOSE 
 
     MKC            
HIGH DOSE 
 
SODIUM 
 (mg/ml) 
 4.275±0.278014 
6.625±0.2780
14 6.175±0.298259 
5.485±0.45595
2 
 
 
CALCIUM 
 (mg/ml) 
 
1.5275±0.09741
45 
4.425±0.5793
32 3.555±0.100125 
5.475±0.42695
6 
 
 
PHOSPHOR
US 
 (U/L) 
 0.45±0.0426224 
1.23±0.74028
2 
0.6175±0.03375
77 
0.635±0.06224
95 
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6.0 RESULTS: 
    CLINICAL SIGNS: 
All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
 Mortality: 
All animals in control and in all the treated dose groups survived throughout 
the dosing period of 28 days. 
 Body weight: 
Results of body weight determination of animals Table no-17 from control and 
different dose groups exhibited comparable body weight gain throughout the dosing 
period of 28 days. 
Food consumption: 
During dosing and the post-dosing recovery period, the quantity of food 
consumed by animals from different dose groups was found to be comparable with 
that by control animals. 
Organ Weight: 
Group Mean Relative Organ Weights (% of body weight) are recorded in 
Table No.20 Comparison of organ weights of treated animals with respective control 
animals on day 29 was found to be comparable similarly. 
Hematological investigations: 
The results of hematological investigations Table no- 21 conducted on day 29 
revealed following significant changes in the values of different parameters 
investigated when compared with those of respective controls; however, the increase 
or decrease in the values obtained was within normal biological and laboratory limits 
or the effect was not dose dependent. 
Biochemical Investigations: 
Results of Biochemical investigations conducted on the day 29th and recorded 
in Table no 22 revealed the following significant changes in the values of hepatic 
serum enzymes studied. When compared with those of respective control. However, 
the increase or decrease in the values obtained was within normal biological and 
laboratory limits. 
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INTERPERTATION: 
 
1)  All the animals from control and all the treated dose groups up to 15ml/kg 
survived throughout the dosing period of 28 days. 
2)  No signs of toxicity were observed in animals from different dose groups during 
the dosing period of 28 days. 
3)  Animals from all the treated dose groups exhibited comparable body weight gain 
with that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be comparable 
throughout the dosing period of 28 days 
5)   Haematological analysis conducted at the end of the dosing period on day 29th, 
revealed no abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29th, no 
abnormalities attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was found 
to be comparable with that of respective controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
150 
 
PHARMACOLOGICAL STUDY 
 LITHOTRIPTIC ACTIVITY 
Table no-26 Effect on urinary output in urolithiasis induced rats  
 
 
Days GP1 GP2 GP3 GP4 GP5 GP6 
0 7.65± 
0.42 
7.42± 
0.40 
7.84± 
0.76 
7.60± 
0.78 
8.55± 
0.92 
8.32± 
0.88 
14 7.85± 
0.66 
6.95± 
0.42**a 
8.40± 
0.95**b 
9.12± 
1.34**b 
10.35± 
1.55**b 
11.32± 
1.66**b 
28 8.36± 
0.72 
6.36± 
0.32**a 
8.66± 
1.25**b 
10.32± 
1.44**b 
11.45± 
1.62**b 
11.92± 
1.72**b 
 
GP1- Normal;   GP2- Lithiatic Control;   GP3-  MK (100mg/kg);  
GP4-MK (200mg/kg); GP5-MK (300mg/kg);  
GP6-Cystone herbal tablets (500mg/kg) 
 
 Values are expressed as mean ± SEM 
 Values were found out by using ONE WAY ANOVA Followed by Newman 
keul’s multiple range tests. 
 **(a) Values were significantly different from normal control (GP1) at P< 0.01 
 **(b) Values were significantly different from Lithiatic control (GP2) at P<0.01    
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Table.no:27 
EFFECT ON URINARY BIOCHEMICAL PARAMETERS ON THE DAY 14 
 
GP1- Normal;   GP2- Lithiatic Control;  GP3-  MK (100mg/kg);  
GP4- MK (200mg/kg); GP5- MK (300mg/kg); GP6 - Cystone herbal tablets 
(500mg/kg)             
 Values are expressed as mean ± SEM 
 Values were found out by using ONE WAY ANOVA Followed by Newman 
keul’s multiple range tests. 
 **(a) Values were significantly different from normal control (GP1) at P< 0.01 
 **(b) Values were significantly different from Lithiatic control (GP2) at P<0.01    
 
GP 
Protein 
(mg/dl) 
Magnesium 
(mg/dl) 
Calcium 
(mg/dl) 
Uric 
acid 
(mg/dl) 
Creatinine 
(mg/dl) 
Oxalate 
(mg/dl) 
Phosphate 
(mg/dl) 
GP1 
71.92± 
2.95 
4.30± 
0.52 
5.68± 
0.50 
8.28± 
0.68 
0.82± 
0.10 
17.86± 
1.45 
35.94± 
2.85 
GP2 
152.32 
± 
5.30**(a) 
1.15 ± 
0.20**(a) 
25.20± 
1.90**(a) 
16.60 ± 
1.60**(a) 
1.61 ± 
0.14**(a) 
30.72 ± 
3.20**(a) 
76.64 ± 
4.30**(a) 
GP3 
88.35 ± 
3.92 **(b) 
2.60 ± 
0.30**(b) 
19.30 ± 
2.15**(b) 
10.60 ± 
0.95**(b) 
0.99 ± 
0.09**(b) 
24.30 ± 
2.45**(b) 
45.60 ± 
3.75**(b) 
GP4 
84.52 ± 
3.55**(b) 
2.82 ± 
0.40**(b) 
13.45 ± 
0.80**(b) 
12.35 ± 
0.84**(b) 
0.92 ± 
0.11**(b) 
22.28 ± 
2.32**(b) 
40.82 ± 
3.22**(b) 
GP5 
85.15± 
3.70**(b) 
2.66 ± 
0.44**(b) 
15.70 ± 
0.60**(b) 
9.95 ± 
0.85**(b) 
0.89 ± 
0.09**(b) 
23.22 ± 
1.92**(b) 
36.25 ± 
2.30**(b) 
GP6 
81.30± 
2.85**(b) 
3.33 ± 
0.58**(b) 
17.68 ± 
0.42**(b) 
8.92 ± 
0.76**(b) 
0.84 ± 
0.10**(b) 
20.22 ± 
1.88**(b) 
35.25 ± 
2.30**(b) 
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Table no-28 EFFECT ON URINARY BIOCHEMICAL PARAMETERS ON 
THE 28TH DAY  
GP 
Protein 
(mg/dl) 
Magnesiu
m 
(mg/dl) 
Calcium 
(mg/dl) 
Uric acid 
(mg/dl) 
Creatinine 
(mg/dl) 
Oxalate 
(mg/dl) 
Phosphate 
(mg/dl) 
GP1 
74.85 
±3.80 
4.30 
±0.45 
7.15 
±0.70 
3.42 
±0.50 
0.92 
±0.30 
17.45 
±1.36 
31.55 
±2.48 
GP2 
163.25 
±8.22**(a) 
1.84 
±0.50**(a) 
21.85 
±1.56**(a) 
13.55 
±1.45**(a) 
1.60 
±0.55**(a) 
50.25 
±4.60**(a) 
80.60 
±4.70**(a) 
GP3 
90.20 
±5.60**(b) 
2.15 
±0.38**(b) 
14.68 
±1.05**(b) 
8.54 
±0.58**(b) 
1.20 
±0.36**(b) 
26.60 
±2.65**(b) 
47.70 
±3.32**(b) 
GP4 
87.50 
±5.40**(b) 
3.92 
±0.53**(b) 
12.40 
±0.95**(b) 
8.30 
±0.45**(b) 
1.22 
±0.40**(b) 
23.45 
±2.55**(b) 
44.30 
±3.16**(b) 
GP5 
83.30 
±4.60**(b) 
3.66 
±0.50**(b) 
11.80 
±0.40**(b) 
7.90± 
0.42**(b) 
1.46 
±0.28**(b) 
21.30 
±2.10**(b) 
42.30 
±2.75**(b) 
GP6 
84.60 
±4.85**(b) 
3.50 
±0.48*(b) 
11.18 
±0.32**(b) 
7.18± 
0.34**(b) 
1.24 
±0.50**(b) 
20.70 
±2.15**(b) 
40.75 
±2.25**(b) 
 
 
 
GP1- Normal; GP2- Lithiatic Control; GP3-  MK (100mg/kg); GP4- MK(200mg/kg); 
GP5- MK(300mg/kg); GP6 Cystone herbal tablets(500mg/kg)             
 Values are expressed as mean ± SEM 
 Values were found out by using ONE WAY ANOVA Followed by Newman 
keul’s multiple range tests. 
 **(a) Values were significantly different from normal control (GP1) at P< 0.01 
 **(b) Values were significantly different from Lithiatic control (GP2) at 
P<0.01    
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Table.no:29 
EFFECT ON SERUM PARAMETERS ON THE 28th DAY 
GP 
Magnesium 
(mg/dl) 
Calcium 
(mg/dl) 
Uric acid 
(mg/dl) 
Creatinine 
(mg/dl) 
Oxalate 
(mg/dl) 
Phosphate 
(mg/dl) 
GP1 
4.94 
±0.58 
10.56 
±1.50 
3.20 
±0.22 
0.44 
±0.25 
6.2 
±0.70 
12.90 
±1.55 
GP2 
1.99 
±0.42**(a) 
17.45 
±2.46**(a) 
9.70 
±1.22**(a) 
1.22 
±0.55**(a) 
13.55 
±1.70**(a) 
29.18 
±3.48**(a) 
GP3 
3.80 
±0.55**(b) 
12.80 
±1.80**(b) 
4.28 
±0.48**(b) 
0.70 
±0.42**(b) 
9.50 
±0.90**(b) 
24.22 
±2.80**(b) 
GP4 
3.96 
±0.20**(b) 
12.80 
±1.55*(b) 
4.12 
±0.43**(b) 
0.75 
±0.45**(b) 
8.80 
±0.85**(b) 
22.78 
±2.68**(b) 
GP5 
3.85 
±0.50**(b) 
11.10 
±1.45**(b) 
3.70 
±0.40**(b) 
0.60 
±0.32**(b) 
8.55 
±0.80**(b) 
18.20 
±1.60**(b) 
GP6 
4.12 
±0.52**(b) 
10.15 
±1.40**(b) 
3.15 
±0.40**(b) 
0.50 
±0.28**(b) 
7.15 
±0.60**(b) 
17.28 
±1.56**(b) 
 
GP1- Normal;    GP2- Lithiatic Control;  GP3-  MK (100mg/kg);  
GP4- MK (200mg/kg);   GP5- MK (300mg/kg);  
GP6 - Cystone herbal tablets (500mg/kg)             
 Values are expressed as mean ± SEM 
 Values were found out by using ONE WAY ANOVA Followed by Newman 
keul’s multiple range tests. 
 **(a) Values were significantly different from normal control (GP1) at P< 0.01 
 **(b) Values were significantly different from Lithiatic control (GP2) at P<0.01    
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RESULT: 
            In the present study, chronic administration of 1% (v/v) ethylene glycol aqueous 
solution to wistar rats resulted in hyperoxaluria. Urinary concentration of the various ions 
investigated varied drastically, following ethylene glycol treatment. 
 
EFFECT OF MKC ON URINARY PARAMETERS ON DAY 14 & 2 
                    The oxalate excretion was 24hr on day 14th & 28th respectively for GP1. It 
increased significantly (P < 0.001) on day 14th & 28th day in GP2 following ethylene 
glycol treatment. Treatment at a dose of MKC 100mg/kg, 200mg/kg and 300mg/kg and 
cystone herbal tablet at a dose of 500mg/kg (GP3 to GP6) reduced the oxalate excretion 
significantly to (P<0.01) on 14th day treatment. Likewise on 28th day, treatment with this 
MK reduced the oxalate excretion significantly to (P<0.01) in (GP3 toGP6) rats 
respectively. The results are shown in the table no: 27 & 28. 
The urinary calcium excretion was increased significantly on day 14th and 28th 
day in GP2 following ethylene glycol treatment. The calcium excretion was significantly 
reduced to treatment with MK at a dose of 100 200 and 300mg/kg and cystone herbal 
tablet at a dose of 500mg/kg (GP3 to GP6) reduce the calcium excretion significantly to 
on 14th day treatment likewise on 28th day calcium excretion was significantly reduced to 
s24hr (P<0.01) in (Gp3 to Gp6) rats respectively. The results are shown in the table no: 27 
& 28. 
Likewise phosphate and creatinine excretion values gradually increased in GP2 on 
the 14th & 28th day. However in (GP3 to GP6) grouped treated animals these elevated 
values were significantly reduced on 14th and 28th day respectively. However, regarding 
creatinine in (GP3 to GP6) these elevated values were significantly reduced on 14th day 
and on 28th day respectively. The results are given in table no:27 & 28.. 
Likewise urinary protein and uric acid concentration increased following ethylene 
glycol treatment in GP2 and it reached maximum respectively on the 14th & 28th day. On 
treatment with MK at a dose of 100,200 and 300mg/kg and cystone herbal tablet at a dose 
of 500mg/kg (GP3 to GP6) the protein and uric acid excretion was restored to near normal 
limits in (GP3 to GP6) for protein on 14thday and on 28th day (p<0.001) and for uric acid 
on 14th day and on 28th day    (P<0.01). The results are tabulated in table no:27 & 28. 
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In GP2 lithiatic control rats, the magnesium level in urine gradually decreased 
following ethylene glycol treatment on the 14th & 28th day . Subsequent administration of 
the MK and cystone herbal tablets enhanced the magnesium excretion significantly on 
14th day & 28th day. 
EFFECT OF MKC ON SERUM PARAMETERS ON DAY 28 
In prophylactic study the serum parameters such as calcium, uric acid, creatinine, 
oxalate, phosphate levels were increased significantly in GP2 (Lithiatic control) following 
ethylene glycol treatment, Treatment with MK at a dose of 100,200 and 300mg/kg  and 
cystone herbal tablet at a dose of 500mg/kg (GP3 to GP6) reduce the all above mentioned 
parameters  significantly. On the contrary the magnesium levels were decreased 
significantly in GP2 (Lithiatic control) following ethylene glycol treatment. After 
treatment with MK at a dose of 100mg/kg, 200mg/kg and 300mg/kg and cystone herbal 
tablet at a dose of 500mg/kg (GP3 to GP6) the magnesium level was restored near to 
normal levels.  
 
INTREPERTATION: 
 
                 Results show increased elimination of oxalate,calcium, phosphate, 
magnesium, uricacid, creatinine which decresed circulating level of those minerals 
and as prevent calculi formation of  kidneys  
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 DIURETIC ACTIVITY  
 
Table no: 30 Diuretic activity of MKC (urine Volume) in 24 h 
 
Group Treatment 
 
Urine Volume 
I Normal saline 10ml/kg 8.10±0.55 
II Frusemide 20mg/kg 12.95±0.94** 
III MKC 100mg/kg 11.25±0.70** 
IV MKC  200mg/kg 12.35±0.85** 
V MKC 300mg/kg 13.15±0.95** 
Values are Mean ± SEM, n=6, **p<0.01. 
 
 
 
 
 
 
 
Table no:31 Natriuretic activity of MKC 
 
 
Treatment Na+ K+ Na+/K+ 
Normal saline 10ml/kg 1.72±0.10 0.72±0.03 2.38 
Frusemide 20mg/kg 3.25±0.25** 0.88±0.04** 3.69 
MKC  100mg/kg 1.98±0.16* 0.72±0.01ns 2.75 
MKC  200mg/kg 2.25±0.18** 0.70±0.02ns 3.21 
MKC 300mg/kg 2.30±0.24** 0.71±0.03ns 3.23 
Values are Mean ± SEM, n=6, *p<0.05, **p<0.01, NS - not significant 
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Results: 
 
Table -30 shows the urine volume collected in 24 h for all the groups. It is 
evident that the MKC treated groups excreted more urine than the control groups. The 
MKC at 100, 200 and 300 mg/kg exhibited comparable effect with that of the 
reference drug Fursemide 20 mg / kg and the results were statistically significant. 
Table -31 shows the sodium and potassium content of the urine for all groups. The 
amount of Sodium excreted was increased for Fursemide treated group; statistically 
significant rise in Na+ excretion was also noticed for MKC treated groups. The 
potassium content excreted in the urine was statistically insignificant for all the 
groups. The Natriuretic effect was calculated by employing the formula Na+ / K+. It 
was found that the MKC treated groups possess favorable Natriuretic effect. The 
present study showed that the MKC significantly increases the urine output and 
excretion of urinary sodium and had no effect on the urinary potassium excretion. 
Diuretics have two separate connotations; increase urinary par se and net loss of 
solute (i.e. electrolyte) and water (i.e. saluretic). These two processes are involved in 
the suppression of renal tubular reabsorption of electrolytes, water and low molecular 
weight organic compounds into the blood stream and a consequence; promote the 
formation of urine (96). An attempt to extrapolate the diuretic action of plant extract 
from rats to man using the activity of Fursemide in the organism as a guideline has 
been reported.  
 
INTERPERTATION: 
 
The results clearly shows that the MKC at doses of 100, 200 and 300 mg / kg 
produced significant dose dependent increase in urinary excretion and urinary sodium 
loss but no effect on urinary potassium loss with respect to control and standard drug 
treated groups. The data demonstrates that the MKC has diuretic effect, Natriuretic 
effect but no potassium sparing effect and is as potent as Fursemide. (97).  
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ANTI-SPASMODIC ACTIVITY 
DoseResponse Relationship Observations of Acetylcholine 
Table no-32 
Si.No Concentration/dose Acetylcholine 
Response (cm) 
1 0.1 ml 2.8cm 
2 0.2 ml 3.4cm 
3 0.4 ml 3.9 cm 
4 0.8 ml 4.5 cm 
5 1.6 ml                      5.2cm 
 
Dose Response Relationship Observations of Atropine 
 
Si.No Concentration/dose atropine 
Response (cm) 
1 0.1 ml - 
2 0.2 ml - 
3 0.4 ml - 
4 0.8 ml - 
5 1.6 ml - 
 
Dose Response Relationship Observations of Acetylcholine and MKC 
Si.No Concentration/dose Acetylcholine + MKC 
Response (cm) 
1 0.1 ml +0.1 ml                      3.3 cm 
2 0.2 ml +0.2 ml 3.7 cm 
3 0.4 ml +0.4 ml 4.4 cm 
4 0.8 ml +0.8 ml 4.7 cm 
5 1.6 ml + 1.6 ml 5.6 cm 
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Comparative Dose Response of Ach and Ach followed by MKC 
Table no-33 
Si No Treatment  Dose(ml) response % of response 
1  
Acetylcholine 
0.1 ml 2.8 cm  
2 0.2 ml 3.4 cm  
3 0.4 ml 3.9 cm  
4 0.8 ml 4.5 cm  
5  1.6 ml            5.2 cm  
6  
Acetylcholine + 
MKC 
0.1 ml +0.1 ml            3.3 cm 17.85 % 
7 0.2 ml +0.2 ml 3.7 cm 8.82 % 
8 0.4 ml +0.4 ml 4.4 cm 12.82 % 
9 0.8 ml +0.8 ml 4.7 cm 4.44 % 
10 1.6 ml + 1.6 ml 5.6 cm 7.69 % 
 
Figure no:13 
 
 
Fig: Comparative dose response relationship of Acetylcholine and MKC on 
excisedrat ileum. 
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RESULTS:-  
 Effect of Acetylcholine on excised rat ileum reflected an increase in 
spasmodic activity (response) with an increase in dose 
 
INTERPERTATION: 
                           From the present study results it was observed that acetylcholine 
(Ach) alone causes contraction of excised rat ileum but when acetylcholine was given 
in presence of MKC there was a marked decrease in contraction of ileum was 
observed. This revealed that MKC possess a high degree of spasmolytic (anti-
spasmodic) activity by blocking cholinergic receptors 
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ANTI – MICROBIAL ACTIVITY 
 
Table No: 34 Anti – Microbial Activity of Mavilingu Kasayam 
 
S.No 
Organism   
(Culture) 
Susceptibility 
Zone size 
Streptomycin zone size 
          
Medicine size 
 
1. 
E.Coli 
 
Sensitive 12mm 21mm 
2. 
   Klebsiella 
pnemoniae 
Resistant 25mm - 
3. 
Pseudomonas 
aeruginosa 
 Resistant  17mm - 
4. 
Streptococcus 
muntant 
Moderate  
Sensitive 
23mm 17mm 
5. 
Staphylococcus 
aureus 
   Sensitive 14mm 24mm 
6. 
Enterococcus 
faecalis 
Moderate  
Sensitive 
20mm 11mm 
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Figure no : 14 Anti – Microbial Activity of Mavilingu Kasayam 
 
Ecoli                                Staphylococcus aureus       
    
  
Pseudomonas aeruginosa                                Streptococcusmutant  
             
       
  
 
Staphylococcus  aureus                                   Enterococcus faecalis                                                                                                  
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Interpretation: 
The drug Mavilingu kasayam anti Microbial activity was compared with 
standard drug Streptomycin for the following pathogens they are E.coli, klebsiella, 
pseudomonas, streptococcus, staphylococcus & enterrococcus the drug mavilingu 
kasayam showed the inhibition of growth of micro organism at 100 micro gram/ml 
concentration for the organism there results represents Mavilingu kasayam potencially 
inhibit the E. coli, staphylococcus and moderately inhibit streptococcus, 
enterrococcus.  
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7. SUMMARY: 
 
 The trial drug MAVILINGU KASAYAM is a herbal formulation selected 
from the text book of AGASTHIYAR 2000, PART 3 (Page no.31) for the 
validation of safety, efficacy and therapeutic potency on kalladaippu. 
 
 The raw drug Mavilingu Vadaku Ver was collected from Nagarkovil, nerunjl 
ver, chirupeelai ver and peramutti ver collected from Tirunelveli. These raw 
drugs was identified and authenticated by Gunapadam Department, Govt. 
Siddha Medical College, Palamkottai, Tamil nadu. 
 
 A review of the literatures and lateral research works reveals that all the 
ingredient of mavilingu kasayam used in treating kalladaippu. 
 
 In siddha literature alteration in diet and water intake increases the vatha and 
pittha dhosa in body it will affect the abana vayu.  So urine will be stagnanted 
in urinary tract.  So salt deposit easily anywhere in the urinary tract and forms 
the stone. 
 
 The ingredient of mavilingu kasayam paeramutti and nerunjil biotransformed 
sweet taste.  The ingredient mavilingam and chirupeelai biotransformed 
pungent taste. Sweet taste neutralizes the vatham and pitham at the same time 
pungent taste neutralize the abana vayu. So these characters very much useful 
to kalladaippu. 
 
 
 Physiochemical analysis shows determination of total ash, insoluble ash and 
moisture content it was within acceptable range. It indicates the longer shelf 
life period. 
 
 TLC result shows variation of Rf values indicates the presences of various 
chemical compounds in this drug. 
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 Biochemical analysis shows the presence of Sulphate, Iron ferrous, Phosphate, 
Unsaturated compound. All of these possess significant potency in the 
elimination of renal calculus. 
 
 ICP-OES analysis of these drug shows heavy metals Like Ca, Na, K, Mg, Zn, 
P,S,Fe. In Mavilingu kasayam, the heavy metals like As, Hg, Cd, Pb,Cu and 
trace element like Ni,Al were below detectable level. This reveals the safety of 
the drug. 
 
 FTIR analysis of mavilingu kasayam revealed the presence of alcohols, 
phenols, alkenes, amines, aliphatic amines, alkyl halides, nitrocompound, 
aromatics esters, saturatedaliphatic, alkynes groups. Alcoholic group of act as 
antimicrobial activity.Phenolic groups has anti microbial, anti oxidant 
activities, which are used in the inhibition of Renal stone. 
 
 SEM photographs that particles are rounded in shapes and sizes are in the 
range from 0.5 micron to 1 micron.The size of the particles enables better 
absorption which denotes that the trial drug could have potent drug delivery. 
 
 Anti microbial activity of mavilingu kasayam potencially inhibits 
Escherchia.coli, staphylococcus and moderately inhibit Streptococcus, 
enterococcus. 
 
 The pharmacological study revealed that trial drug mavilingu kasayam 
possesses a lithotriptic (anti lithiatic), diuretic and antispasmodic activity.  The 
experimental evidence obtained in the laboratory model. 
 
 
 Toxicological study of both acute and sub-acute toxicity study were carried 
out in animal model Wistar albino rat according to the OECD guidelines. The 
acute toxicity of test drug there were no physical and behavioral changes 
observed in female Wister rats of 5mg/kg, 50mg/kg, 300mg/kg, 1000mg/kg 
and 2000mg/kg to rats during 14 days. 
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Body weight of all animals did not reveal any significant change as compared 
to vehicle control group.Food consumption of all group animals was 
normal.Mortality was not observed in any treatment groups. 
 
 The sub-acute toxicity after the repeated dose of 28 days was done. The 
mortality, functional observations, hematological and biochemical 
investigations were made. There was no significant change seen in the normal 
values. Thus the toxicological study of the test drug greatly establishes the 
safety and gives the justification for long time administration. 
 
 Thus the drug mavilingu kasayam was very effective and safe for treating 
kalladaippu without causing any adverse effects. 
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8. CONCLUSION 
 
The trial drug MAVILINGU KASAYAM was selected for the elaborate study 
of its efficacy on Kalladaippu.  From the literature review, physiochemical, 
pharmacological, microbiological,   bio chemical, Instrumental analysis.  It has been 
concluded that Mavilingu kasayam has got a good Lithotriptic (Anti lithiatic), 
Diuretic, Anti – spasmodic activities and hence effective for Kalladaippu. 
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